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ABSTRACT 
Anticancer Activity of Peach and Plum Extracts Against Human Breast Cancer In Vitro 
and In Vivo. (August 2008) 
Giuliana Doris Noratto Dongo, B.S., Universidad Nacional Agraria La Molina, Peru; 
M.S., Universidad Nacional Agraria La Molina, Peru 
Co-Chairs of Advisory Committee:   Dr. Luis Cisneros-Zevallos  
        Dr. David Byrne 
                                                                            
 
Commercial varieties of peaches and plums contain a mixture of phenolics that may 
possess anticancer activity. Our objectives were to evaluate extracts from a commercial 
variety of yellow fleshed peach „Rich Lady‟ (RL) and of the red fleshed plum „Black 
Splendor‟ (BS) on tumor breast cells in vitro and in vivo, to elucidate the molecular 
mechanisms behind the cancer growth-suppression of the phenolics identified in peach 
and plum extracts for their chemopreventive potential and to evaluate the tumor growth-
suppression in vivo. 
The RL extract preferentially inhibited the proliferation of the estrogen-independent 
MDA-MB-435 breast cancer cells over the estrogen-dependent MCF-7 or the normal 
MCF-10A breast cells. Similarly, BS extracts, though less effective than RL extracts, 
showed greater effects on MDA-MB-435 cells compared to the other cell lines. 
Fractionation of RL extracts into different groups of phenolic compounds allowed the 
identification of a fraction of phenolic acids (F1) with the major components of 
chlorogenic and neo-chlorogenic acid with potential in chemoprevention because of the 
relatively high growth-inhibition exerted on MDA-MB-435 and low toxicity exerted on 
MCF-10A cells. The F1 isolated from RL, and its major components, chlorogenic and 
neo-chlorogenic acids, triggered the extrinsic and intrinsic apoptotic pathways. The 
extrinsic death-receptor pathway involved the activation of caspase-8 followed by 
caspase-6, caspase-7, and PARP cleavage. By targeting the intrinsic pathway, the pro-
apoptotic proteins cytochrome c, EndoG and AIF were released from mitochondria. The 
relatively higher cell-growth inhibition exerted by neo-chlorogenic acid was associated 
with its ability to inhibit the pro-survival Akt pathway. In contrast, F1 isolated from the 
iv 
 
 
 
red flesh genotype BY00P6653, induced apoptosis mainly through the intrinsic 
mitochondrial pathway upon sustained MAPK-ERK1/2 phosphorylation.  
The tumor growth-suppression of RL extracts was confirmed in vivo. Moreover, a 
dose-dependent decrease in lung metastasis was found, even at doses that showed no 
effect in tumor growth-suppression.  
These results suggest that peach phenolics may have potential in therapy and 
chemoprevention of metastatic breast cancer. Specifically chlorogenic and neo-
chlorogenic acids, widely distributed among food plants, may be a useful therapeutic tool 
for targeting multiple cell signaling pathways in the treatment and chemoprevention of 
metastatic breast cancer.  
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CHAPTER I 
INTRODUCTION 
 
Breast cancer is the second leading cause of cancer-related deaths in American US 
women and continues to be the most diagnosed type of cancer. The American Cancer 
Society has estimated that there will be 182,460 new cases of invasive breast cancer and 
67,770 new cases of in situ breast cancer among women in the US during 2008.
1
 Unlike 
the hormone receptor-positive MCF-7 breast cancer in which the use of hormone therapy 
has achieved a significant reduction in cancer incidence, the estrogen receptor negative 
MDA-MB-435, which have an inherent capacity to metastasize, are being treated with 
chemotherapeutics that kill cells indiscriminately. 
Death, and most of the complications associated with breast cancer are due to 
metastasis. It has been reported that approximately 10-15% of patients with breast cancer 
develop distant metastasis.
2
 Because of the lack of accuracy on predicting the risk of 
metastasis in patients with primary tumors, most of them are being treated with adjuvant 
therapy to prevent or eradicate the breast tumor cells that might have already spread to 
distant sites by the time of diagnosis. Therefore, many women who could be cured by 
local treatment alone, which includes surgery and radiotherapy, are „over-treated‟ and 
experience the toxic side effects of chemotherapy unnecessarily.
2
 
 
Cancer 
The process of carcinogenesis  
Cancer is a disease of deregulation of cell growth, a multistep process that takes place 
over a period of time due to the accumulation of mutations in a single cell, resulting in 
gradual phenotypic changes, from a normal to a preneoplastic cell that progress to 
neoplastic. Cancer occurs through the loss or mutations of genes that cause  deregulation 
of signal transduction pathways, abnormal amplification of growth signals, and aberrant 
expression of genes that ultimately transform the cells into invasive cancer.
3
  
 
__________________ 
This dissertation follows the style of Journal of Medicinal Food. 
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The different stages in carcinogenesis are: initiation (days), promotion (5-10 years), 
and progression (1–5 years).4, 5 Initiation is irreversible and includes an initial chemical 
or physical carcinogenic stimulus directly targeting DNA. Promotion is usually a 
relatively slow and reversible process leading to accumulation of pre-malignant cells 
dividing abnormally. Progression is generally irreversible and leads to the final stage of 
carcinogenesis with tumor growth and acquisition of invasiveness and metastatic 
potential.
6
 The progression from primary to metastatic tumor implies the acquisition of 
phenotypes that allow these cell lines to invade, disseminate and colonize distant sites.
7
 
The passage from pre-malignant to malignant cell involves activation of proto-
oncogenes and/or inactivation of tumor suppressor genes, resulting in the generation of 
mutant cells with selective advantages.
3
 The six essential alterations in cell physiology 
that lead to malignant growth are: self-sufficiency in growth signals, insensitivity to 
growth-inhibitory (antigrowth) signals, evasion of programmed cell death (apoptosis), 
unlimited replicative potential, sustained angiogenesis, and tissue invasion and 
metastasis.
6
  
In this context, the goal of cancer preventive therapy, or "chemoprevention," is to 
eliminate premalignant cells or to block the progression of normal cells into cancerous 
cells.  
Chemoprevention 
Dr. Michael Sporn was the first who proposed the approach of chemoprevention to 
effectively control cancer before the complex series of genetic and epigenetic events that 
result in invasive and metastatic malignancy have occurred. A more modern and 
complete definition of chemoprevention includes the use of natural or pharmacological 
agents to suppress, arrest or reverse carcinogenesis, at its early stages.
8
 Good 
chemopreventive agents should interfere with one or more of the stages of 
carcinogenesis. The efficacy of a novel chemopreventive agent is measured following the 
same procedure applied to a new drug.
5
 It must satisfy the following requirements: (1) 
primary prevention in high risk healthy individuals; (2) cancer prevention in individuals 
that already had developed pre-malignant lesions; (3) prevention of secondary forms of 
cancers in patients already treated for a primary cancer.
9, 10
 The achievement of clinical 
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evidence for cancer reduction would be the final endpoint of all three aspects of 
chemoprevention. 
Most chemoprevention experiments in animal models are performed in groups of 
animals that have been treated with a extremely high doses of a carcinogen, or have a 
genetic defect that result in a short latency period. However, in humans the latency period 
is long (10-20 years). Effective chemopreventive agents can work to raise the quality of 
millions of people by extending the latency period for the onset of cancer, often more 
than doubling this parameter.
8
 
Targets of chemoprevention 
Cancer chemopreventive agents target specific transcription factors and signal 
transduction pathways abnormally altered. Deregulation of transcription factors and 
signal transduction pathways cause altered gene expression that leads to imbalanced 
proliferation, differentiation, apoptosis, and eventually to malignant transformation.
3
  
Transcription factors 
Agents that target transcription factors for breast cancer treatment include the selective 
estrogen receptor (ER) modulators (SERMs). However, about 20–30% of ER positive 
and all ER-negative breast cancers fail to be prevented by SERMs.
11
  
Cell signaling pathways 
Multiple alterations in signal transduction pathways are observed during the process of 
mammary carcinogenesis. Signaling cascades are mediated by several families of protein 
kinases that control the phosphorylation process and alters enzymatic activity, resulting in 
regulation of gene expression, metabolism, proliferation, differentiation, and apoptosis.
3
  
One of the cell signaling pathways that may play an important role in breast cancer 
disease is the mitogen activated protein kinases (MAPKs). It is upregulated in ̴ 30% of 
human breast tumors; indeed, modulation of these pathways may be a promising strategy 
for cancer chemoprevention.
12
 
MAPKs are the family of kinases that transduce signals from the cell membrane to the 
nucleus in response to a wide range of stimuli including stress.
13
  The MAPK signaling 
pathways modulate gene expression, mitosis, proliferation, motility, metabolism, and 
programmed death or apoptosis. MAPKs consist of three family members: the 
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extracellular signal-regulated kinase (ERK), c–Jun NH2-terminal kinase (JNK); and the 
p38-MAPK. ERK is generally activated in response to growth stimuli whereas JNK and 
p38-MAPK are known to be simultaneously activated in response to a variety of cellular 
and environmental stresses that trigger apoptosis.
13
 Although most studies relate ERK 
activation to cell proliferation, others show that activation of the ERK cascade promotes 
contrary cellular responses that vary upon cellular context,
14
 including cell proliferation, 
cycle arrest, differentiation, senescence, or apoptosis.
15
  
In addition to MAPK, mutation and amplification of the PI3K/Akt cascade is frequent 
in breast cancer.
3, 16
 The PI3K/Akt signaling pathway plays a critical role in breast cancer 
development and promotes breast cancer cell survival and resistance to treatment.
17
 The 
Akt (Protein Kinase B) is a major downstream effector of PI3Ks that regulates various 
biological processes such as cellular growth, differentiation, and survival via activating or 
repressing multiple factors and cofactors.
18
 The anti-apoptotic effect of Akt may be 
mediated through its ability to phosphorylate and inactivate Bad and other death 
proteins.
19
 Akt can also regulate apoptosis at a post-mitochondrial level by inhibiting 
activation of caspase-9 and -3 by post-translational modification of a cytosolic factor 
downstream of cytochrome c and before activation of caspase-9.
20
 Thus, by targeting the 
PI3K/Akt signaling, it would be possible to modulate some cellular responses, including 
cell proliferation and protection from apoptosis.
21
  
Apoptosis 
Apoptosis is referred to as synonymous to “programmed cell death”.  A mechanistic 
“endpoint” or “point of no return.” It occurs when there is a massive caspase activation, 
loss of mitochondrial transmembrane potential, complete permeabilization of the outher 
mitochondrial membrane or exposure of phosphatidylserine residues that emit “eat me” 
signals to neighboring normal cells.
22
 Apoptosis is essential to maintain the balance 
between cell growth and cell death. It can be induced through the crosstalking extrinsic 
death receptor pathway and the intrinsic mitochondria pathway.
23
   
a. The death receptor pathway or Fas-mediated apoptosis may be induced by ligation of 
the Fas-receptors
24
 leading to the activation of caspase-8, an initiator of an apoptotic 
process that is followed by  the activation of effectors caspase-3, caspase-7 and 
caspase-6 and mitochondrial damage.
25
 Caspases are synthesized in normal cells as 
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inactive proenzymes but they can rapidly be activated by autoproteolytic cleavage or 
cleavage by other caspases at specific aspartic acid residues. During apoptosis, 
caspases acting as upstream signal transducers are called “initiator caspases”, whereas 
the proteolytically activated downstream caspases are called “effector caspases”. The 
effector caspases act on a variety of substrates resulting in proteolysis of cellular 
proteins and death by apoptosis. The best characterized caspase substrate is poly-
(ADP-ribose) polymerase (PARP), a nuclear protein implicated in DNA repair. 
b. The intrinsic mitochondrial pathway is controlled by the Bcl-2 family of proteins, 
which are in turn regulated by several stimuli, including stress by reactive oxygen 
species (ROS) and cytotoxic compounds.
23
 When this pathway is activated, the pro-
apoptotic proteins permeabilize the outer mitochondrial membrane resulting in the 
release of proteins from the intermembrane space. The Bcl-2 family members act as 
either pro- or anti-apoptotics. The pro-apoptotic members of the Bcl-2 family, Bax, 
Bak and Bid form channels or regulate preexisting channels in the mitochondrial 
membrane, whereas the antiapoptotic Bcl-2 and Bcl-xL have the opposite effects on 
membrane channel formation. Unlike Bax, which exists as a monomer either in the 
cytosol or loosely
  
attached to the outer mitochondrial membrane,
26
 Bak is 
constitutively associated to the mitochondria.
27
 Upon induction of apoptosis, the 
cytosolic Bax translocates to the mitochondria, and simultaneously with this 
translocation, Bax oligomerizes into large complexes.
28, 29
 Like Bax, Bak homo-
oligomerizes during apoptosis. Both have a degree of functional cooperation during
  
the channel formation and trigger the release of pro-apoptotic proteins from the 
mitochondria.
30
 
On the other hand, the antiapoptotic proteins Bcl-xL and Bcl-2, reside in the outer 
mitochondrial membrane and blocks cytochrome c release that follows the activation 
of Bax and Bak, thus preventing it from catalyzing caspase activation.
26, 31
 
Additionally, the crosstalk between extrinsic
 
and intrinsic pathways occurs when 
caspase-8 is activated by the death receptor pathway and targets the mitochondrial 
pathway through the cleavage of Bid, another pro-apoptotic  Bcl-2 family member.
23
 
Several proteins, including cytochrome c, Smac/DIABLO, HtrA2/Omi, 
endonuclease G (EndoG) and apoptotic inducing factor (AIF), normally sequestered 
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in the mitochondria induce or promote apoptosis once released into the cytosol.
23
 
Cytochrome c, binds Apaf-1 (apoptosis protease-activating factor-1), which permits 
the oligomerization to form the apoptosome. This allows the recruitment of multiple 
procaspase-9 molecules to the complex, facilitating their activation. After that, 
caspase-9 can cleave and activate executioner caspase-3, -6 and -7 as well.
32
 
Endo G, and AIF represent caspase-independent apoptotic pathways initiated from 
the mitochondria. Once translocated from mitochondria to nuclei in response to 
apoptotic stimuli, EndoG cleaves chromatin DNA into nucleosomal fragments 
independently of the caspases.
33
 Likewise, AIF shuttles to the nucleus and induces 
peripheral chromatin condensation, large-scale fragmentation of DNA and, finally, 
cytotoxicity.
34
 An overview of the mechanisms that induce apoptosis or regulate the 
survival pathway is shown in Figure 1. 
 
 
 
 
Figure 1. Overview of molecular targets for chemoprevention. 
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The use of agents that potentially attack the mitochondria is appealing for cancer 
treatment since unlike the nuclear genome, the mitochondrial DNA is not protected by 
histones, which makes it more susceptible to damage, and the DNA repair capacity of 
mitochondria is limited.
35
 Research on natural compounds that may act as novel 
chemotherapeutics by targeting the mitochondria pathway and induce apoptosis on 
estrogen receptor negative breast cancer is intense.
36, 37
 
Diet and breast cancer 
A diet rich in fruit and vegetables has been recommended for preventing many 
diseases. Epidemiological and human studies indicate that a lowered risk of cancer is 
related to antioxidant-rich diets.
38, 39
 Indeed, specific dietary factors may contribute to 
breast cancer prevention.
40
 
Likewise, such studies indicate that regional differences in breast cancer incidence are 
most likely partially attributable to life long dietary habits.
41
 Incidence and mortality of 
breast cancer is up to 5-fold higher in Western countries than in some Asian countries.
42
 
Dietary patterns in Asian countries include a diet high in n-3 polyunsaturated fatty acid 
and phytochemicals present in fruit and vegetables. This is consistent with evidence 
showing that dietary components strongly associated with breast cancer include fat and 
phytochemicals. Though time of intake appears to be important, and effective protection 
may be achieved if one is exposed to a dietary factor that lowers breast cancer risk early 
in life.
42
  
In general, there are many biologically plausible reasons why consumption of plant 
foods might slow or prevent the appearance of cancer. These include the presence in 
plant foods of potentially anticarcinogenic substances as carotenoids, vitamin C, vitamin 
E, selenium, dietary fibre (and its components), dithiolthiones, isothiocyanates, indoles, 
phenols, protease inhibitors, allium compounds, plant sterols, and limonene. The 
observations on the anticarcinogenic potential of all of these compounds have come from 
animal and in vitro studies. These phytochemicals have shown to be able to affect every 
one of the stages of the cancer process.
43, 44
 So far, the National Cancer Institute (NCI) 
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has identified about 40 edible plants whose phytochemicals have potential as 
chemopreventive agents.
5
 
Role of polyphenols in cancer 
Plant polyphenols have shown potential as natural anticarcinogenic compounds that 
can act in each one of the steps of the process of carcinogenesis. According to their 
mechanisms of action may have potential as cancer-blocking and/or cancer-suppressing 
agents  
Cancer-blocking agents act during the initiation stage protecting cellular targets by 
scavenging reactive oxygen species (ROS) and other oxidative species, enhancing 
carcinogen detoxification, modifying the carcinogen uptake and metabolism, and 
enhancing DNA repair. Cancer-suppressing agents inhibit the promotion and progression 
stages after the formation of pre-neoplastic cells by interfering with cell cycle regulation 
(cyclin dependent proteins), regulation of signal transduction pathways (MAPKs, TGF-β 
serine-threonine kinase signaling and β-catenin pathways),45  transcription (NF-kB 
activation),  and apoptosis (activation of pro-apoptotic genes and pro-apoptotic 
proteins).
45, 46
 Plant polyphenols may target one or more of the molecular pathways in 
cancer cells including the regulation of the angiogenesis process. During progression, 
tumor angiogenesis is critically important for the growth of solid tumors and is mediated 
by the initiation of blood vessel formation. Since this is mediated by endothelial cells, it 
is easy to achieve active concentrations of antiangiogenic agents. 
Furthermore, the mixture of phytochemicals, as they are naturally in foods, might be 
more effective in cancer chemoprevention than single compounds. This is known as 
“combination chemoprevention” that explains why low doses of chemopreventive agents 
differing in their mode of action may increase efficacy and minimize toxicity, through 
synergistic mechanisms.
5
 In addition, potential apoptotic inducers from plants have 
shown to induce apoptosis in neoplastic cells but not in normal cells. 
47-49
 Therefore, the 
study of these compounds with respect to their abilities to induce apoptosis and the 
underlying molecular mechanisms may provide valuable information for their potential 
application in cancer therapy and chemoprevention. 
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Phytochemicals in stone-fruits 
Commercial varieties of peaches and plums contain a mixture of phytochemicals that 
include phenolic acids, flavonols, anthocyanins, procyanidins and carotenoids.
50, 51
  
Specifically, compounds identified in peaches and plums are the hydroxycinnamates 
chlorogenic acid and neo-chlorogenic acid, the flavan 3-ols catechin, and epicatechin; the 
flavonols quercetin 3-glucoside, 3-rutinoside, 3-galactoside, 3-xyloside and 3-
rhamnoside; the anthocyanins cyanidin 3- galactoside, 3- glucoside, 3- rutinoside, and 3-
acetylglucoside and procyanidin dimers and trimers.
51
 
Several in vivo and in vitro studies have shown that phenolics extracted from plants 
have potential in chemoprevention and chemotherapy of breast cancer.
52-57
 They may act 
as cancer blocking agents due to their ability to scavenge free radicals, and/or cancer 
suppressing agents, due to their capacity to target different signal transduction pathways 
and preventing tumor development by inducing tumor cell apoptosis.
5
  
Unlike flavan 3-ols, flavonols, anthocyanins and procyanidins, research on 
chemoprevention and anticancer activity of the phenolic acids chlorogenic and neo-
chlorogenic acids is limited. Even more, when these phenolic acids are compared to the 
other groups of polyphenols, they appear to be less potent in modulating cell viability, 
and inducing apoptosis.
36, 58, 59
 However, most studies failed to assess the toxicity of the 
more potent polyphenols on noncancerous cells. 
Chlorogenic acid and neo-chlorogenic acid   
Chlorogenic and neo-chlorogenic acids are the esters formed between caffeic acid and 
quinic acid in position 5 or 3 respectively (Figure 2). These compounds have been subject 
of many health related claims that include many properties as antioxidant dietary 
compounds. In vitro, they scavenge free radicals,
60
 increase resistance of LDL to lipid 
peroxidation,
61
 and inhibit DNA damage.
62, 63
 Chlorogenic acid and neo-chlorogenic acid 
are also present in coffee
64
 and some herbs widely used in traditional Chinese medicine 
with a wide range of biological activities.
65
 In addition, the role of chlorogenic acid and 
caffeoylquinic acid derivatives as cancer suppressing agents has been reported for several 
human cancer cells other than breast cancer.
66
 Alternatively it has been reported that 
chlorogenic acid could act as cancer blocking agent, protecting against carcinogen-
10 
 
 
 
inducers through its capacity to up-regulate the cellular antioxidant enzymes and suppress 
the ROS-mediated pro-inflammatory and oncogenic pathways.
67
 Likewise, chlorogenic 
acid may act either by enhancing the intrinsic cellular tolerance against oxidative insults 
and activating survival/proliferation pathways in non-tumor cells.
68
  
 
 
 
 
Figure 2. Chemical structure of caffeoylquinic acid derivatives: chlorogenic acid (A) 
and neo-chlorogenic acid (B). 
 
 
 
On the other hand, most reports indicate that the cancer suppressing activity of 
phenolic compounds is mediated by modulatory actions on intracellular signaling 
pathways rather than the conventional hydrogen donating properties.
69
 Therefore, a clear 
understanding of the mechanisms of action of these phenolic acids, either as antioxidants 
or modulators on cell signaling and the influence of their metabolism on these properties 
are very important for their evaluation as anticancer agents. 
So far, the role of chlorogenic acid and caffeoylquinic acids derivatives as 
chemopreventive agents has been supported by evidence from in vitro studies showing 
the cell growth suppression and modulation of different cell signaling pathways on 
leukemic cells,
70
 oral tumor cells,
71
 brain tumor
72
 and several other human tumor cells.
66
 
However, each one of these studies reported different molecular mechanisms behind the 
cancer suppressing properties of chlorogenic acid. This suggests that the molecular 
targets of chlorogenic acid are particular in each cancer cell line studied. 
Likewise, animal studies have shown that chlorogenic acid might provide protection 
against cancer-induction in the tongue,
62, 73
 the colon,
74
 the intestine,
75, 76
 and the 
Caffeic acid
Quinic acid
(A) (B)
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stomach,
77
  as well as against genotoxicity and DNA breakage in gastric mucosa.
63
 In this 
context, chlorogenic acid may be acting as antioxidant and/or repressor of metabolic 
activation of carcinogens rather than as a modulator of intracellular signaling pathways. 
In addition, the real protection in vivo would be dependent on its bioavailability. 
Bioavailability of chlorogenic acid 
The antioxidant and anticarcinogenic properties of chlorogenic acid and caffeoylquinic 
acid derivatives have been well established in vitro and animal studies. However, these 
phenolic acids must be absorbed through gastrointestinal tract firstly in order to achieve 
the chemopreventive and protective effects in vivo. Several studies have reported the 
absorption kinetics of chlorogenic acid after intravenous administration,
78
 though the 
absorption kinetics through the gastrointestinal tract is rather scarce. It has been reported 
that after intragastric administration of chlorogenic acid in rats, a rapid absorption and 
quick distribution is achieved followed by a slow elimination.
65
 Likewise, human studies 
have shown that chlorogenic acid is differentially absorbed and/or metabolized, with a 
large inter-individual variation,
79
 and depends largely on its metabolism by the gut 
microflora.
80
 In addition, neo-chlorogenic acid is rapidly metabolized and/or stored in 
organs such as the liver.
79
 
Most importantly, the concentration in plasma after drinking a cup of coffee (1-
3µmol/L)
79
 is ̴ 14 to 4 fold the active concentrations required to induce apoptosis in 
malignant cells in vitro (0.07-0.7 µmol/L).
70
 Therefore, it is very likely that the anticancer 
chemopreventive properties of chlorogenic acid can be translated in clinical trials, though 
it has to be confirmed by using in vivo models before application in preclinical models. 
Mouse models in human breast cancer  
Mouse models have made an important contribution to the understanding of breast 
cancer progression and metastasis. The main reasons for using laboratory mouse models 
are: i) the mouse is a mammalian organism that shares many anatomic, physiological and 
genetic similarities with humans; ii) the mouse germ line can be easily manipulated 
whereby genes may be over-expressed or inactivated, even in a time or tissue-especific 
manner.  
12 
 
 
 
The mouse models commonly used to investigate breast cancer include xenografts and 
genetically engineered mice (GEM).
81
 The use of GEM allows the study of effects of 
over-expressed or down-regulated genes that may have significant role in human breast 
cancer, such as the loss of tumor suppressor genes and the effects of gain of function in 
oncogenes.
81
 In contrast, the growth of breast cancer cell lines as xenografts allows 
investigation in the in vivo environment, which includes the complex tumor–stromal cell 
interactions that facilitate tumor formation and progression.
81
 
Xenograft model  
Xenografts consist of an injection of cells into a live animal, usually a rodent, in order 
to study the actions of the cells in an in vivo environment. The use of a xenograft model 
in breast cancer research allows for the examination of cells in the context of the in vivo 
environment, and the modeling of complex multicellular and cell–extracellular matrix 
interactions, inflammation and angiogenesis that are involved in the initiation and 
progression of breast cancer.
81, 82
 
The model used for tumor transplantation can be orthotopic or the conventional flank 
subcutaneous model (s.c.). The orthotopic transplantation refers to the delivery of cancer 
cells to the anatomic location or tissue from which a tumor was derived and responds to 
the application of “seed and soil” hypothesis. This model resembles more closely human 
cancers including tumor histology, vascularity, gene expression, responsiveness to 
chemotherapy and metastatic biology.
83
 In addition, this model provides an opportunity 
to study the metastatic process and many aspects of the metastatic cascade that are 
bypassed using experimental metastasis models.
84
 
In contrast, by using transplantable s.c. tumor models, we can evaluate the rate of 
primary tumor growth at subcutaneous sites. Such transplantable models are often labeled 
as „non-metastatic‟. Even so, both systems will reinforce our ability to select the most 
appropriate therapeutic agents for recommended use in clinical studies.
84
 
Limitations of xenograft models 
The main limitations when using a xenograft model are the use of cell lines that may 
not represent the most common types of breast cancer observed in the clinic and the fact 
that xenografts must be established in immunocompromised mice to prevent immune 
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rejection. The later eliminates the ability to examine the role of the immune system in 
tumor development and progression in xenografts.
85, 86
  
In addition, there have been reports that significant differences exist for angiogenesis 
between transplanted and autochthonous tumors, which may reduce the predictive power 
of xenografts to clinical tumors.
87, 88
 Furthermore, it has been reported that about one-
third of the compounds with an in vivo activity tested by xenograft models, had 
correlation with activity in some phase II clinical trials. These characteristics may 
potentially reduce the predictive power of xenograft models in pre-clinical testing.
89
 The 
limitations of xenograft mouse models have opened new opportunities and challenges for 
the application of novel genetically engineered mouse models that may be used to 
validate the tumor response, investigate pharmacodynamic markers of drug action, and 
evaluate toxicity during the development of new drugs.
90
 
Application of xenograft models in breast cancer research 
Xenografts studies represent a useful preclinical tool for testing new agents, to test and 
validate protocols and for further exploration of the biological basis of drug responses.
91
  
When studying breast cancer,  the xenograft model allows the use of cell lines that 
represent all of the sequential stages of the progression in the breast cancer disease.
82
 
Likewise, xenograft models are often used in metastasis research, and offer excellent 
insights into invasion properties and progression studies.
81
 Metastatic capacity is an 
inherent feature of breast tumors, which develop in regional lymph nodes and in distant 
organs, including bone, lung, liver, and brain.
2
 Metastasis frequently arises from 
orthotopic tumors,
82
 in which implantation of cancer cells in the skin or mammary fat 
pad, precedes the formation of primary tumors and the subsequent formation of 
metastasis. These steps resemble the multiple stages involved in malignant breast cancer 
development in patients.
84
 
Xenograft models and natural compounds 
Several studies have shown the effectiveness of plant extracts in tumor-growth 
suppression by using the mice xenograft model, thus showing that the in vitro 
antiproliferative results can be effectively extrapolated to the in vivo situation.
52, 92-95
 
Furthermore, the specific phenolic compounds identified in peaches and plums
51
 have 
14 
 
 
 
been shown to inhibit tumor growth and metastasis with xenograft models. For example, 
cyanidin 3-glucoside, as component of an anthocyanin rich extract, was reported to 
inhibit tumor growth in vivo,
96, 97
 and invasion via repression of metalloproteinases.
97
 
Proanthocyanidins showed antitumor activity and increased the anti-tumor activity of the 
chemotherapeutic doxorubibin,
98, 99
 quercetin inhibited the growth and exhibited pro-
apoptotic activities in xenografted MDA-MB 435 cells into nude mice,
52
 and phenolic 
acids from propolis induced abortive mitosis and massive necrosis in malignant cells.
100
 
The treatment with caffeic acid derivatives of C6 glioma cells grown as xenografts on 
nude mice induced a significant dose dependent decrease in tumor growth and reduced 
the number of mitotic cells.
95
 
Finally, all these polyphenols either as components in plant extracts or as isolated 
compounds have shown potential for tumor growth-suppression in vitro and in vivo. The 
use of cell lines is ideal for studies examining signal pathways and gene regulation. 
While the xenograft model resembles the complex interactions that are involved in breast 
cancer progression and is an important tool to test and validate novel treatment strategies. 
However, there are no reports with either in vitro or in vivo, regarding the breast cancer 
suppression properties of stone fruit extracts. Therefore the findings from this study will 
set the basis for chemopreventive and chemotherapeutic recommendations using peaches 
and plums as source of such novel anticancer compounds. 
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CHAPTER II 
BREAST CANCER CELL GROWTH-INHIBITION OF PHENOLICS IN 
COMMERCIAL VARIETIES OF PEACHES AND PLUMS 
 
Synopsis 
Commercial varieties of peaches and plums have been reported to contain a mixture of 
phenolics that may exert anticancer activity. Many of these phenolic compounds have 
been shown to inhibit the proliferation of a number of cancer cell lines. However, there 
are differences in the amounts and distribution of these phenolics among commercial 
varieties. Our objective was to evaluate the cancer suppression activity of extracts from a 
commercial variety of yellow fleshed peach „Rich Lady‟ (RL) and of a red fleshed plum 
„Black Splendor‟ (BS) and identify the phenolic fractions that may possess potential as 
chemopreventive and/or chemotherapeutic natural compounds.  
The peach RL extract effectively inhibited the proliferation of the estrogen-
independent MDA-MB-435 breast cancer cell line. The concentration to inhibit 50% of 
cell proliferation (IC50) was ~ 42 mg/L for this cell line compared to a IC50 of ~130 
mg/L and ~ 515 mg/L for the non cancerous breast line MCF-10A and the estrogen 
dependent breast cancer line MCF-7 respectively. Similarly, BS extracts showed greater 
effects on MDA-MB-435 cells compared to the other breast cancer or the normal breast 
cell lines. In general, BS extracts were less effective than RL extracts. Within all RL and 
BS fractions, Fraction 3 (flavonoids) and Fraction 4 (procyanidins) were the most potent 
against the three cell lines. The order of potency of RL fractions against MDA-MB-435 
was F3 ̴ F4 > F1 > F2. 
The antiproliferative activity of pure compounds identified in F3 and F1 confirmed that 
quercetin 3β-glucoside is the bioactive compound in F3, with the same level of toxicity  
on the estrogen independent MDA-MB-435 breast cancer and on breast epithelial MCF-
10A cells (IC50 = 1.9 ± 0.2 and 1.8 ± 0.3 respectively).  However, we confirmed that 
phenolic acids present in F1: chlorogenic and neo-chlorogenic acids have potential as 
chemopreventive dietary compounds because of the relatively high growth inhibition 
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exerted on the estrogen independent MDA-MB-435 and low toxicity exerted in the 
normal MCF-10A cells. 
 
Introduction 
Breast cancer is the second leading cause of cancer-related deaths in US women and 
continues to be the most diagnosed type of cancer. The American Cancer Society has 
estimated that there will be 182,460 new cases of invasive breast cancer and 67,770 new 
cases of in situ breast cancer among women in the US during 2008.
1
 Most deaths from 
breast cancer are the result of distant metastasis rather than primary tumor burden and 
chemotherapy is based on the use of non-specific cytotoxic agents that kill cells 
indiscriminately. 
Commercial varieties of peaches and plums have been previously quantified for their 
antioxidant activity and level of phenolic compounds.
50, 101, 102
 They contain a mixture of 
phytochemicals that include phenolic acids, flavonols, anthocyanins, procyanidins and 
carotenoids.
50, 51
 Several in vivo and in vitro studies have shown that these groups of 
phenolic compounds found in plant extracts have potential in chemoprevention and 
chemotherapy of breast cancer.
52-57
 The chemopreventive activity of phenolic compounds 
may result from their ability to scavenge free radicals, but they also inhibit the promotion 
stage of carcinogenesis by targeting different signal transduction pathways and may 
prevent tumor development by inducing tumor cell apoptosis (programmed cell death).
5
 
Our goal is to study the anti-proliferative activity of phenolics present in peaches and 
plums in terms of high chemopreventive potential and low toxicity in normal cells and 
identify their bioactive compounds.  
 
Materials and Methods 
Plant material 
Commercial varieties of yellow-fleshed peach „Rich Lady‟ (RL) and of red-fleshed 
plum „Black Splendor‟ (BS) grown in California, were collected at a mature firm stage 
and stored at 2-4°C until use (less than 5 days). Upon arrival at Texas A&M University, 
the fruits were frozen after removal of the stones and kept at -20°C until use. 
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Extraction of phenolic compounds 
100 g of frozen fruit (flesh plus skin) was blended with 300 mL of methanol and left at 
4°C overnight. Methanolic extracts were filtered through whatman #1 filter paper and 
methanol evaporated at 45°C using a rotavapor (Büchi, Switzerland). Aqueous extracts 
were frozen at -80ºC and freeze-dried in a freeze dryer (FTS® Systems, Inc., Stone 
Ridge, NY) at -50 ˚C and at 200 mm Hg of pressure.   These extracts, designated as 
“crude extract,” were further used for the cell culture assays by applying different doses 
based on total phenolic content measured spectophotometrically by Folin-Ciocalteu 
colorimentric method.
103
 Crude extract was re-suspended in culture medium and sterile 
filtered for the cell growth proliferation assay. 
Fractionation of phenolic compounds 
The crude extract was fractionated into phenolic acids (F1), anthocyanins (F2), 
flavonols (F3) and procyanidins/polymeric anthocyanins (F4) by solid phase extraction 
using C18 cartridges.
104
 Briefly, the aqueous extract was adjusted to pH 7.0 with 5 N 
NaOH. The extract was loaded in SEP Pack C18 cartridge previously conditioned to pH 
7.0 with 50 mL of 100% methanol and 50 mL of nanopure water (pH 7.0). The neutral 
phenolics were absorbed in the cartridge while the phenolic acids were not. The cartridge 
was washed with 50 mL of water (pH 7.0). The water from wash was combined with the 
phenolics that were not adsorbed in the cartridge and adjusted to pH 2.0. This mixture of 
compounds was loaded into a second cartridge previously conditioned at pH 2.0 with 50 
mL 100% methanol and 50 mL nanopure water pH 2.0. Phenolic acids bound to the 
matrix of the second cartridge (F1) were later eluted with 50 mL 100% methanol. After 
adjusting the pH to 2.0 in the first cartridge, elution of anthocyanins was accomplished by 
passing 50 mL of 16% acetonitrile at pH 2.0 (F2). The flavonols were eluted using 50 mL 
100% ethyl acetate (F3) and the anthocyanin polymers using 50 mL of 100% methanol 
(F4). Fractions were evaporated using a speed vac (Savant SC100) (F1, F3 and F4) or a 
rotavapor (F2) (Büchi, Switzerland) followed by freeze-drying  (FTS® Systems, Inc., 
Stone Ridge, NY) at -50 ˚C and at 200 mm Hg of pressure and kept under nitrogen gas at 
– 20 ᵒC for use in cell culture.  
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HPLC-DAD analysis  
The RL and BS crude extracts as well as their fractions were analyzed using a Waters 
(Milford, MA, USA) HPLC system. An AtlantisTM C18 5 µm, 4.6 mm x 150 mm column 
and a 4.6 mm x 20 mm guard column was used for the separation of phenolic 
compounds. The mobile phase was composed of solvent A (nanopure water adjusted at 
pH=2.3 with 2N HCl) and solvent B (acetonitrile HPLC grade). The elution was as 
follows: isocratic conditions from 0-5 min with 85% A and 15% B; gradient conditions 
from minute 5 to 30 starting with 85% A and ending with 0%, and starting with 15% B 
and ending with 100%; then, isocratic conditions from minute 30 to minute 35 with 0% A 
and 100% B.
105
 The mobile phase was used at a flow rate of 1 mL/min and 20 µL of 
sample previously dissolved in MeOH and filtered through a 0.2µm PTFE filter was 
injected. Identification of phenolic compounds was performed by comparison of retention 
times and UV-visible spectral data of the chromatographic profiles with known standards. 
Cell lines 
 Cell lines used in this study were obtained from the American Type Culture Collection 
(ATCC, Manassas, VA). MCF-7, the estrogen-positive human breast cancer cells, were 
cultured using Dulbecco‟s modified Eagle‟s medium (DMEM) high glucose, L-
glutamine, 25 nM HEPES buffer, pyridoxine hydrochloride, without sodium pyruvate 
and without phenol red, supplemented with 5 mL insulin (1 mg/mL), 10% (v/v) fetal 
bovine serum (FBS) and 1% Penicillin-Streptomycin antibiotic mix. MDA-MB-453, the 
estrogen-negative human breast cancer cells, were cultured using Dulbecco‟s modified 
Eagle‟s medium (DMEM) with L-glutamine, 4.5 g/L glucose and without sodium 
pyruvate, supplemented with 10% (v/v) Fetal Bovine Serum (FBS) and 1% Stripticin-
penicillin antibiotic mix. MCF-10A, the breast epithelial cells, were cultured in 
Dulbecco‟s modified Eagle‟s medium/F12 (DME/F12) supplemented with 5% (v/v) FBS, 
1% Stripticin-penicillin antibiotic mix, 1mL EGF (10µg/mL), 5 mL insulin (1 mg/mL), 
250 µl hydrocortisone (1 mg/mL), and 20 µL cholera toxin. Culture media were supplied 
by Invitrogen (Gibco™, Invitrogen Corp., Grand Island, NY). Cells were maintained at 
37 ºC with a humidified 5% CO2 atmosphere. 
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Cell proliferation 
Cell growth and the concentration to inhibit the cell growth by 50% (IC50) was 
assessed by using an electronic coulter counter (Z1™ Series, Beckman Coulter, Inc). 
Cells were seeded and incubated for 24 h to allow cell attachment before exposure to 
varying concentrations of extracts. A pretreatment number of cells (0-time value) was 
established and medium was replaced containing the crude extracts or fractions at 
different concentrations. Total phenolics were quantified by the Folin-Ciocalteau 
method,
103
 and doses were based on their phenolic content and expressed as mg 
chlorogenic acid equivalent/L. Fresh medium along with compounds, was replaced every 
48 h. Crude extracts, F1 and F2 were re-dissolved in culture medium and sterile-filtered 
before use; whereas F3 and F4 were dissolved in ethanol, all cultures contained 1 mL/L 
each of ethanol. Each experiment was carried out in triplicate, and results were expressed 
as means ± SD. The difference in number of cells between final and 0-time represents net 
growth. 
Statistical analysis 
Quantitative data represent mean values with the respective standard deviation (SD) or 
standard error of the mean (SE) corresponding to 3 or more replicates. Data were 
analyzed by one-way analysis of variance (ANOVA) using SPSS version 15.0 (SPSS 
Inc., Chicago, IL). Post-hoc Tukey pairwise comparisons were used (p<0.05). 
 
Results and Discussion 
HPLC-DAD analysis of phenolic compounds in Rich Lady (RL) and Black Splendor 
(BS) extracts and fractions 
The RL and BS crude extracts and fractions (Figure 3) were analyzed by HPLC-DAD. 
Identification of phenolic compounds was performed at 280 nm by comparison of 
retention times and UV-visible spectral data with known standards (Figure 4).   
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Figure 3. Scheme of fractionation used for RL and BS crude extracts.  
 
 
 
The chromatographic profile of RL extract (Figure 4A) indicated the presence of neo-
chlorogenic acid (peak 1
a, RT = 4 min), cyanidin 3β-glucoside (peak 2, RT = 7.2 min) 
and quercetin 3ß-glucoside (peak 3
b
, RT = 16.2 min).  Chromatograms of RL fractions 
showed that the main compounds in F1 were neo-chlorogenic acid (Peak 1
a
, RT = 4 min) 
and chlorogenic acid (peak 1
b, RT = 7 min). The F2 presented cyanidin 3β-glucoside 
(peak 2, RT = 6.8 min). In F3, flavonols with the typical glycosylation at position 3 were 
found
106
 in between 15 and 17 min. We identified quercetin 3β-rutinoside (peak 3a , RT = 
15.9 min) and quercetin 3ß-glucoside (peak 3
b
, RT = 16.3 min). F4 was composed by 
procyanidins and traces of cyanidin 3β-glucoside (peak 2). 
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Figure 4. Chromatograms at 280 nm of RL (A) and BS (B) extracts and the four 
fractions obtained using solid phase extraction with a C18 cartridge. (1
a
) neo-
chlorogenic acid; (1
b
) chlorogenic acid; (1
c
) unidentified caffeoylquinic acid; (2) 
cyanidin 3β-glucoside; (3a)  quercetin 3β-rutinoside; (3b) quercetin 3ß-glucoside ; (4) 
catechin derivative. 
 
 
 
Chromatograms of BS extract (Figure 4B) indicated the presence of cyanidin 3β-
glucoside (peak 2), the flavonols quercetin 3β-rutinoside (peak 3a), quercetin 3ß-
glucoside (peak 3
b
) and based on the spectral characteristics, a catechin derivative was 
also found (peak 4, RT = 8 min). The BS fractions presented profiles similar to those 
found for RL fractions: F1 contained neo-chlorogenic acid (Peak 1
a
), and a caffeoylquinic 
acid with same UV spectra of chlorogenic acid, though different retention time (peak 1c, 
RT = 11 min), other minor compounds with the characteristic spectra of 
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hydroxycinnamic acid derivatives were detected as well. The F2, F3 and F4 presented 
same phenolic profiles than the found in RL fractions. 
In general, our findings regarding the phenolic profile of RL and BS extracts and 
fractions are in agreement with the previously reported for California peach and plum 
varieties.
51
 Among them, peaches contain mainly the phenolic acids: chlorogenic and 
neo-chlorogenic acids; the flavan-3-ols: catechin, catechin derivatives and procyanidins; 
the flavonols: quercetin and quercetin derivatives; and small amounts of anthocyanins: 
cyanidin 3β-glucoside and 3 β-rutinoside.51, 107 The red fleshed plum varieties contain the 
same pattern of phenolics combined with high amounts of anthocyanins.
51, 102
 Moreover, 
the study on California RL peach using HPLC-MS analysis
51
 confirmed the structure of 
main phenolics identified in our F1, F2 and F3. These phenolics have been the subject of 
many health-related claims supported by in vitro and in vivo studies and related to their 
properties as antioxidants and anti-carcinogenic dietary compounds.
52, 68, 108, 109
  
Cell proliferation  
The yields of RL and BS extracts after methanol extraction were 5.8% ± 0.8 and 5.6% 
± 0.5 (g total phenolics/100g fruit) respectively. The RL and BS extracts exerted cell 
growth-inhibition against both cell lines, the estrogen dependent MCF-7 and the estrogen 
independent MDA-MB-435. Within the range of 0-35 mg/L, RL extracts suppressed the 
proliferation of MDA-MB-435 cells, whereas the MCF-7 estrogen receptor positive cells 
were several times more resistant to RL extracts (active concentrations in the range 0-
500mg/L). A similar pattern of dose and time-dependent cell growth suppression in both 
cell lines was found for BS extracts although the dose range was higher than the active 
dose range found for RL (0-70 and 0-1000 mg/L for MDA-MB-435 and MCF-7 
respectively) (Figure 5).  
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Figure 5. Cell  proliferation of MCF-7 estrogen receptor positive (A), and MDA-
MB-435 estrogen-receptor negative (B) breast cancer cells. Cells were treated with 
different doses of extracts from RL and BS. Values are mean of three replicates ± 
SE. Asterisk indicates significant difference between treatments at the same 
incubation time (days). (*) p ≤ 0.05, (**) p ≤ 0.01. 
 
 
 
Several studies have reported the association of fruit and vegetable consumption with 
reduced cancer risk.
46, 110, 111
 Edible plants, because of their safety and the fact that they 
are not perceived as “medicine,” are increasingly being considered as sources of natural 
anticancer compounds. This is supported by evidence that many non-nutrient compounds 
in plant foods are effective inhibitors of human breast cancer cell proliferation in vitro.
112
 
The antiproliferative activity of fruit extracts as sources of dietary phytochemicals has 
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been previously reported for several cancer cell lines and most of the studies have 
attributed their enhanced antiproliferative activity to interactions of individual 
phytochemicals suggesting a synergistic or additive effect.
113-115
 However, most of these 
studies fail to assess the toxicity of these natural compounds in normal cells.  
Cell growth-suppressive activity of Rich Lady (RL) and Black Splendor (BS) extracts 
against epithelial MCF-10A breast cells 
To evaluate the potential toxicity of RL and BS extracts to non-tumor cells, we added 
the MCF-10A breast epithelial cells to our study (Figure 6). At 35, 70 and 140 mg/L, RL 
suppressed the proliferation of MCF-10A by 0%, 30% and 93% respectively. The BS 
extracts also inhibited the growth of MCF-10A, although to a lesser degree. Within the 
range 55-220 mg/L, BS extracts suppressed the proliferation of MCF-10A by 5 to 28%.  
MCF-10A cells were more resistant to the extract-mediated growth suppression than 
MDA-MB-435 cells. At concentrations that RL and BS extracts suppressed the growth of 
MDA-MB-435 cells by 50% (42 mg/L and 54 mg/L respectively), RL and BS extracts 
inhibited the growth of MCF-10A by merely  ~ 15% and 6% respectively, demonstrating 
the preferential suppression of these extracts on the growth of MDA-MB-435 breast 
carcinoma cells. The 50% inhibitory concentrations (IC50s) for RL and BS extracts for the 
three cell lines used in our study are shown in Table 1.  
Cell growth suppressive activity of RL and BS fractions 
To identify the specific compounds with chemopreventive and chemotherapeutic 
potential for breast cancer treatment, the four fractions obtained by solid phase extraction 
were tested for their cell growth inhibition activity. The yields of F1, F2, F3 and F4 for 
RL were 54 ± 11, 73 ± 23, 40 ± 10, and 12 ± 6 (mg total phenolics/100 g fruit fresh 
weight), whereas the yields for BS were 30 ± 18, 200 ± 6, 67 ± 15 and 61 ± 11 (mg total 
phenolics/100 g fruit). The RL fractions exerted a dose-dependent cell growth-inhibition 
within different range of concentrations. The order of potency against MDA-MB-435 was 
F4 ≥ F3 > F1 > F2 for RL fractions.  
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Figure 6. A representative evaluation of the concentration-dependent impact of 
methanolic extracts from the commercial variety of peach RL and plum BS on the 
net growth of human MDA-MB-435 breast cancer cells and the epithelial MCF-10A 
breast cells. Values are mean of three replicates ± SE. Asterisk indicates significance 
difference compared to untreated control (**) p ≤ 0.01. 
 
 
 
Table 1. The concentration to inhibit the cell growth by 50% (IC50) values (mg 
chlorogenic acid equiv./L) of yellow-fleshed peach Rich Lady (RL) and of red-
fleshed plum Black Splendor (BS) extracts for the growth suppression of estrogen 
dependent MCF-7, estrogen independent MDA-MB-435, and epithelial MCF-10A 
breast cells.  
Cell Line 
IC50 (mg chlorogenic acid equiv./L) 
Rich Lady (RL) Black Splendor (BS) 
MCF-7 515
2
 925
1
 ± 70 
MDA-MB-435 42
1
 ± 4 54
1
 ± 8 
MCF-10A 130
1
 ± 36 223
1
 ± 103 
1
Average of three or more independent determinations ± SD. 
2
Average of two 
determinations. 
 
 
 
The active growth-inhibition doses for F3 and F4 were from 5 to 20 mg chlorogenic 
acid equiv./L, whereas F1 and F2 were less potent with active dose range from 40 to 80 
mg chlorogenic acid equiv./L (Figure 7A). A similar pattern was observed for BS 
fractions; however, F2 (anthocyanins rich fraction) appears more potent than F1 
(phenolic acid rich fraction). The estrogen independent MCF-7 cells were more resistant 
to RL and BS fractions with active growth-inhibition doses reached at levels as high as ~ 
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100-150 mg/L (F3 and F4) or ~ 300-500 mg/L (F1 and F2) (data not shown). This may 
indicate that the chemopreventive effect of RL and BS polyphenols in breast cancer is not 
mediated by modulation of estrogen nuclear receptors as has been reported for phyto-
oestrogens.
116
 
 
 
 
 
Figure 7. A representative evaluation of the concentration-dependent impact of RL 
and BS fractions on the net growth of human MDA-MB-435 breast cancer cells (A) 
and the epithelial MCF-10A breast cells (B). Values are mean of three replicates ± 
SE. Asterisk indicates significance difference compared to untreated control (*) p ≤ 
0.05. 
  
Rich Lady Fractions (mg chlorogenic acid equiv./L)
0 50 100 150 200 250 300
N
e
t 
G
ro
w
th
 (
%
 o
f 
c
o
n
tr
o
l)
-40
-20
0
20
40
60
80
100
120 F1 
F2 
F3 
F4 
Rich Lady Fractions (mg chlorogenic acid equiv./L)
0 20 40 60 80
N
e
t 
G
ro
w
th
 (
%
 o
f 
c
o
n
tr
o
l)
-50
0
50
100
F1 
F2 
F3 
F4 
Black Splendor Fractions (mg chlorogenic acid equiv./L)
0 20 40 60 80
N
e
t 
G
ro
w
th
 (
%
 o
f 
c
o
n
tr
o
l)
-50
0
50
100
F1 
F2 
F3 
 F4 
(A) MDA-MB-435
(B) MCF-10A
Black Splendor Fractions (mg chlorogenic acid equiv./L)
0 50 100 150 200 250 300
N
e
t 
G
ro
w
th
 (
%
 o
f 
c
o
n
tr
o
l)
-40
-20
0
20
40
60
80
100
120 F1 
F2 
F3 
F4 
*
**
***
**
* * *
*
*
* **
*
*
*
*
*
*
**
*
**
*
*
*
*
*
* *
*
* *
27 
 
 
 
We further evaluated the chemopreventive potential of RL and BS fractions by 
assessing their dose-dependent cell growth inhibition on the breast epithelial MCF-10A 
cells (Figure 7B). We found that F3 (flavonol) and F4 (procyanidins) were the most 
potent in inhibiting the growth of MCF-10A within the same range of active 
concentrations for MDA-MB-435 (5-20mg/L). However, MCF-10A were more resistant 
to F1 (phenolic acids) and F2 (anthocyanins), as reflected for their higher IC50 values 
(Table 2). These results suggest that phenolic acids present in F1,  mainly chlorogenic 
and neo-chlorogenic acids
51
 may have potential as chemopreventive and 
chemotherapeutic natural compounds against metastasis cancer since they target 
preferentially the MDA-MB-435 cancer cells with low toxicity to normal cells.
5
 
 
 
 
Table 2. IC50 values (mg chlorogenic acid equiv./L) Rich Lady (RL) and Black 
Splendor (BS) fractions for the suppression of growth of estrogen dependent MCF-
7, estrogen independent MDA-MB-435 and epithelial MCF-10A breast cells.  
Cell Line 
  
IC 50 (mg chlorogenic acid equiv./L) 
MCF-7 MDA-MB-435 MCF-10A 
RL BS RL BS RL BS 
F1 ̴ 210 ̴ 250 301 ± 10 621 ± 9 431 ± 8 > 2402 
F 2 ̴ 600 ̴ 220 851 ± 9 561 ± 14 2231 ± 38 471 ± 18 
F 3 ̴ 110 ̴ 200 101 ± 3 161 ± 2 4.51 ± 0.7 131 ± 3 
F 4 ̴ 140 ̴ 180 101 ± 9 121 ± 5 61 ± 3 161 ± 6 
1
Average of three or more independent determinations ± SD. 
2
Average of two 
determinations. 
 
 
 
Previous studies have reported the growth inhibitory effect of plant extracts against 
different cancer cells lines and identified the most active fraction of polyphenols. 
However, most of the studies have found compounds other than phenolic acids as the 
most active. Groups of polyphenols found to possess the highest antiproliferative activity 
on different cancer cell lines were the anthocyanin fraction from potato extracts,
117
 
anthocyanins and flavonols from blueberries,
118
 and procyanidins from apples.
109
 
However, these studies failed to assess the toxicity of the most active fractions on non-
cancerous cells. Even more, the antiproliferative activity of phenolic acids (i.e. 
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chlorogenic acid and caffeoylquinic acid derivatives) has been controversial and highly 
dependent on the cell line. These phenolic acids can enhance the intrinsic cellular 
tolerance against oxidative insults either by activating survival/proliferation pathways or 
by increasing antioxidant potential as reported for the human hepatoma cell HepG2,
68
 or 
by exerting a dose-dependent inhibition of cell proliferation as reported for sweet potato 
leaf extract
66
 on  human cancer cells such as stomach cancer (Kato III),  colon cancer 
(DLD-1), and  promyelocytic leukemia cell (HL-60).  
Previous studies have reported the growth inhibitory effect of plant extracts against 
different cancer cells lines and identified the most active fraction of polyphenols. 
However, most of the studies have found compounds other than phenolic acids as the 
most active. Groups of polyphenols found to possess the highest antiproliferative activity 
on different cancer cell lines were the anthocyanin fraction from potato extracts,
117
 
anthocyanins and flavonols from blueberries,
118
 and procyanidins from apples.
109
 
However, these studies failed to assess the toxicity of the most active fractions on non-
cancerous cells. Even more, the antiproliferative activity of phenolic acids (i.e. 
chlorogenic acid and caffeoylquinic acid derivatives) has been controversial and highly 
dependent on the cell line. These phenolic acids can enhance the intrinsic cellular 
tolerance against oxidative insults either by activating survival/proliferation pathways or 
by increasing antioxidant potential as reported for the human hepatoma cell HepG2,
68
 or 
by exerting a dose-dependent inhibition of cell proliferation as reported for sweet potato 
leaf extract
66
 on  human cancer cells such as stomach cancer (Kato III),  colon cancer 
(DLD-1), and  promyelocytic leukemia cell (HL-60).  
Cell growth suppressive activity of pure compounds present in F1 and F3 
The main compounds found in F1 and F3, the phenolic acids chlorogenic and neo-
chlorogenic acids, and the favonols quercetin 3 β-glucoside and quercetin 3β-rutinoside 
were obtained as pure standards from Sigma-Aldrich (St Louis, MO), and tested for their 
growth-suppressive activity against the estrogen dependent MCF-7, the estrogen 
independent MDA-MB-435 breast cancer cells and the non cancerous MCF-10A cells. 
The most potent inhibitor of cell proliferation was quercetin 3ß-glucoside, with order of 
potency: MDA-MB-435 ̴ MCF-10A > MCF-7. The active dose range for cell growth-
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suppression for MDA-MB-435 and MCF-10A was 2-3 mg/L, whereas the active dose 
range for MCF-7 was relatively high ( ̴ 10-25 mg/L, data not shown). On the other hand, 
the chemically related quercetin 3β-rutinoside did not exert growth inhibition on any of 
the cell lines tested (Figure 8). In contrast, the phenolic acids chlorogenic and neo-
chlorogenic acids  induced growth suppression on the estrogen receptor-negative MD-
MB-435 cells with no effect on the growth of breast epithelial MCF-10A cells up to the 
doses tested (60 mg/L) (Figure 8). Even though, both chlorogenic and neo-chlorogenic 
acids have been reported to exert almost the same antioxidant activity;
119
 they differ in 
their growth suppressive activity against MDA-MB-435 breast cancer cells (IC50 = 17 and 
10 mg/L for chlorogenic acid and neo-chorogenic acid respectively) (Table 3). This 
indicates a structure-activity relationship that may identify neo-chlorogenic acid as a 
more potent bioactive compound against metastatic cancer. The order of sensitivity of 
MDA-MB-435 cells to the tested compounds follow quercetin 3 β-glucoside > neo-
chlorogenic acid > chlorogenic acid. It is interesting to find that chlorogenic and neo-
chlorogenic acids, which are widely distributed in fruits and vegetables, may have 
potential as chemopreventive and chemotherapeutic natural compounds, since they target 
preferentially the MDA-MB-435 cancer cells with no toxicity on normal cells. 
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Figure 8. Representative curves showing the concentration-dependent growth 
suppression of the phenolic acids: chlorogenic acid and neo-chlorogenic acid and the 
flavonols: quercetin 3β-glucoside and quercetin 3β-rutinoside on the estrogen 
independent MDA-MB-435 breast cancer cells (A) and the epithelial MCF-10A 
breast cells (B). Cells were incubated with various concentration of standards 
dissolved in DMSO and net growth was measured at 3 days using a cell counter. 
Values are mean ± SE, n=3. Asterisk indicates significance difference compared to 
untreated control (*) p ≤ 0.05. 
 
 
 
Table 3. IC50 values (mg/L) of pure compounds present in F1 and F3 of the yellow 
fleshed peach RL for the suppression of growth of MDA-MB-435 estrogen 
independent breast cancer cells and the normal MCF-10A breast cells. 
Compound 
IC 50 (mg/L) 
MDA-MB-435 MCF-7 MCF-10A 
Chlorogenic acid 17
2
 ± 4 > 60
2
 > 60
1 
Neo-chlorogenic acid  10
2
 ± 3 > 60
2
 > 60
1 
Quercetin 3β-glucoside 1.92 ± 0.2 ̴ 232 1.81 ± 0.3 
Quercetin 3β-rutinoside > 601 > 602 > 601 
1
Average of three or more independent determinations ± SD. 
2
Average of two 
determinations. 
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Conclusion  
Peaches and plums contain a mixture of phenolic compounds that preferentially inhibit 
the growth of the estrogen independent MDA-MB-435 breast cancer cells over either the 
estrogen independent MCF-7 breast cancer cells or the breast epithelial MCF-10A cells. 
In general, RL extracts were more effective than BS extract in inhibiting the proliferation 
of the three cell lines, with order of sensitivity MDA-MB-435 > MCF-10A > MCF-7. We 
found that F1 from RL (phenolic acid fraction), may possess chemopreventive and 
chemotherapeutic potential. The identification of active compounds with 
chemopreventive potential may lead to the development of natural supplements that exert 
low or no toxicity to normal cells. The main compounds identified in F1 from RL, 
chlorogenic and neo-chlorogenic acids did not inhibit the growth of the non-cancerous 
MCF-10A cells up to the doses tested (60 mg/L,  ̴ 5-6 fold the IC50 for MDA-MB-435). 
These results have important clinical implications because chlorogenic acid and neo-
chlorogenic acid are widespread among food plants including vegetables and fruits and 
constitute an integral part of the human diet.  
 
32 
 
 
 
CHAPTER III 
PHENOLIC ACIDS OF PEACH RICH LADY FRACTION F1 AND ITS ACTIVE 
INGREDIENTS CHLOROGENIC AND NEO-CHLOROGENIC ACIDS TARGET 
MULTIPLE CELL SIGNAL TRANSDUCTION PATHWAYS ON MDA-MB-435 
BREAST CANCER CELLS 
 
Synopsis 
Several plant polyphenols have been reported to inhibit carcinogenesis. Based on the 
approach of identifying natural compounds with chemopreventive potential, we found 
that phenolic acids from peach extracts selectively inhibited the growth of estrogen-
independent MDA-MB-435 breast cancer cells. Our objective was to elucidate the 
molecular mechanisms behind the anticancer activity of a phenolic acid fraction extracted 
from a commercial peach variety („Rich Lady‟; RL) and its major components 
chlorogenic acid and neo-chlorogenic acid on MDA-MB-435. The cell signaling 
pathways triggered by the tested compounds were assessed with Western blots and 
immunofluorescence microscopy. The results showed a relatively higher potency of neo-
chlorogenic acid in inhibiting cell proliferation that was associated to inhibition of the 
pro-survival Akt pathway. Whereas all, RL phenolic acid fraction F1, chlorogenic and 
neo-chlorogenic acid triggered extrinsic and intrinsic apoptotic pathways. The extrinsic 
death receptor pathway induced the activation of caspase-8 followed by caspase-6, 
caspase-7, and PARP cleavage. The intrinsic mitochondrial apoptotic pathway mediated 
the release of pro-apoptotic proteins cytochrome c, EndoG and AIF from the 
mitochondrial outer membrane. Cytochrome c in the cytosol activated caspase-9 and may 
later contribute to cleavage of caspase-6 and caspase-7 as well. AIF and EndoG shuttled 
from mitochondria to nucleus where they might have contributed, at least in part, to DNA 
condensation and fragmentation, and subsequent cell death. The early and sustained 
activation of two members of the mitogen-activated protein kinases (MAPKs), ERK1/2, 
and p38 triggered the up-regulation of the mitochondrial pro-apoptotic Bax, and release 
of cytochrome c. In addition,  crosstalk between both the intrinsic and the extrinsic 
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apoptotic pathways was confirmed by using the broad spectrum caspase inhibitor zVAD-
fmk, which down regulated the mitochondrial pro-apoptotic Bax as well.  
Our results are significant because they show how phenolic acids present in F1 and 
widely distributed among plant extracts that constitute an integral part of the human diet 
may be used as therapeutic tool for targeting multiple cell signaling pathways in 
treatment and prevention of metastatic breast cancer.  
 
Introduction 
Breast cancer is the second leading cause of cancer death in women in the US and 
continues to be the most diagnosed type of cancer. The American Cancer Society has 
estimated that there will be 182,460 new cases of invasive breast cancer among women in 
the US during 2008.
1
  
Our previous study has shown that phenolic compounds from peaches and plums 
preferentially suppressed the growth of the estrogen receptor negative MDA-MB-435 
metastatic breast cancer cells. The phenolic acid fraction from a commercial variety of 
peach „Rich Lady, RL‟ and its major components, the caffeoylquinic acid derivatives 
chlorogenic acid and neo-chlorogenic acid showed chemopreventive and therapeutic 
potential due to the relatively high cell growth-suppression on MDA-MB-435 and low or 
no toxicity on the non-cancerous breast cells.  
Chlorogenic and neo-chlorogenic acids constitute an integral part of the human diet; 
they are widespread among food plants with well established antioxidant and free radical 
scavenger activities. Structurally, chlorogenic acid is the ester formed between caffeic 
acid and quinic acid in position 5.  Isomerisations of the quinic acid in position 3, (3-O-
caffeoylquinic acid) constitute the neo-chlorogenic acid (Figure 9). These compounds 
have been subject of many health related claims that include many properties as 
antioxidant dietary compounds. In vitro, they scavenge free radicals,
60
 increase resistance 
of LDL to lipid peroxidation,
61
 and inhibit DNA damage.
62, 63
 Chlorogenic acid is also a 
major phenolic compound in some herbs widely used in traditional Chinese medicine 
with wide range of biological activities.
65
 In addition, the growth suppression activity of 
caffeic acid, chlorogenic acid and caffeoylquinic acid derivatives in different human 
cancer cells other than breast cancer has been reported.
66
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Figure 9. Chemical structure of chlorogenic acid (A) and neo-chlorogenic acid (B). 
 
 
 
Cancer is a disease of dysregulation of cell growth. The process of carcinogenesis 
occurs through the loss or mutations of genes that cause  deregulation of signal 
transduction pathways, abnormal amplification of growth signals, and aberrant 
expression of genes that ultimately transform the cells into invasive cancer.
3
 Unlike the 
hormone receptor-positive breast cancer in which the use of hormone therapy has 
achieved a significant reduction in cancer incidence, the estrogen receptor negative 
tumors are being treated with chemotherapeutics that kill cells indiscriminately. Research 
on natural compounds that may act as novel chemotherapeutics by targeting abnormally 
altered signaling pathways, decreasing the cell growth and/or inducing apoptosis of 
metastatic breast cancer is intense. 
Apoptosis or programmed cell death is essential to maintain the balance between cell 
growth and cell death, it can be induced through extrinsic death receptors or through the 
intrinsic mitochondria pathway, in addition a crosstalk between both pathways ocurs.
23
   
The death receptor pathway or Fas-mediated apoptosis may be induced by ligation of 
the Fas-receptors,
24
 leading to activation of caspase-8, an initiator of an apoptotic process 
that is followed by  activation of the effectors caspase-3, caspase-7 and caspase-6 and 
mitochondrial damage.
25
 The mitochondria pathway is controlled by the Bcl-2 family of 
proteins. Members of this family act as either pro- or anti-apoptotic. When this pathway 
is activated, the pro-apoptotic proteins form channels that permeabilize the outer 
mitochondrial membrane, which results in the release of proteins from the intermembrane 
Caffeic acid
Quinic acid
(A) (B)
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space. Several proteins, including cytochrome c, Smac/DIABLO, HtrA2/Omi, EndoG 
and AIF, normally sequestered in the mitochondria induce or promote apoptosis once 
released into the cytosol.
23
 Several stimuli, including stress by reactive oxygen species 
(ROS) and cytotoxic compounds have shown to activate this pathway.
23
  
Furthermore, natural plant extracts and phytochemicals appear to target the 
mitochondrial pathway with the mitogen activated protein kinase pathway (MAPK) key 
to this targeting.
14
 MAPKs are known to be simultaneously activated in response to a 
variety of cellular and environmental stimuli including stresses.
13, 120
 
120
 Chlorogenic acid 
has been reported to trigger p38 MAPK-dependent apoptosis in leukemic cells.
70
 In 
addition, caspase-8 activated by the death receptor pathway also targets the mitochondria 
pathway through cleavage of Bid, another pro-apoptotic  Bcl-2 family member.
23
  
Several studies have identified specific cell signaling pathways targeted by natural 
compounds, 
45, 121
 yet there are still many unknowns. Recent studies suggest that the 
chemopreventive effects of phenolic acids may be ascribed to their ability to modulate 
components of cell signaling pathways. Yet the overall effects of these compounds and 
specifically, caffeoylquinic acid derivatives in such pathways are largely unknown and 
differ upon cell context.
68, 122
 Therefore, there is a need to study the molecular pathways 
targeted by these natural compounds that make them effective against the estrogen 
independent breast cancer MDA-MB-435 cell line and non toxic to the non cancerous 
cells.  
 
Materials and Methods 
Chemicals 
The Folin-Ciocalteu reagent, dimethyl sulfoxide (DMSO) and N-acetyl cysteine 
(NAC) were purchased from Fisher Scientific (Pittsburgh, PA). Ethanol, methanol and 
ethyl acetate were purchased from VWR International (Bristol, CT). Chlorogenic acid, 
neo-chlorogenic acid and p38 inhibitor (SB 202190) were obtained from Sigma-Aldrich 
(St Louis, MO). The general caspase inhibitor zVAD-fmk was purchased from BD 
Bioscience (San Jose, CA), MEK1/2 inhibitor (U0126), used for ERK1/2 inhibition, and  
antibodies for phospho-ERK, phospho-p38, cytochrome c, cleaved caspase 3, 6, 7, 8, and 
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9 were purchased from Cell Signaling Technology Inc. (Beverly, MA) Antibodiesfor 
phospho-c-jun, β-actin, and ERK1/2 were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA). Bcl-2 and Bax were purchased from Fisher (Houston, TX). c-Jun, p38, 
Bim, Akt, EndoG, and AIF were purchased from eBioscience (San Diego, CA), and 
phospho-Akt1 was purchased from Millipore  (Temecula, Ca). 
Plant material 
The commercial variety of yellow-fleshed peach „Rich Lady‟, (RL) grown in 
California, was collected at a mature firm stage and stored at 2-4°C until use (less than 5 
days). Upon arrival at Texas A&M University, the fruits were frozen after removal of 
stones and kept at -20°C until use. 
Extraction of RL phenolic acid fraction F1 
100 g of frozen fruit (flesh plus skin) was blended with 300 mL of methanol and left at 
4°C overnight. The methanolic extract was filtered through whatman #1 filter paper and 
methanol evaporated at 45°C using a rotavapor (Büchi, Switzerland). The phenolic acid 
fraction F1was isolated by solid phase extraction (SPE) using C18 cartridges.
104
 Briefly, 
the aqueous extract was adjusted to pH 7.0 with 5 N NaOH. The extract was loaded in 
SEP Pack C18 cartridge previously conditioned to pH 7.0 with 50 mL of 100% methanol 
and 50 mL of nanopure water (pH 7.0). The neutral phenolics were absorbed in the 
cartridge while the phenolic acids were not. The cartridge was washed with 50 mL of 
water pH 7.0. The water from the wash was combined with the phenolics not adsorbed in 
the cartridge and adjusted to pH 2.0. This mixture was loaded into a second cartridge 
previously conditioned at pH 2.0 with 50 mL 100% methanol and 50 mL nanopure water 
pH 2.0. The phenolic acid fraction bound to the matrix of the second cartridge was later 
eluted with 50 mL 100% methanol. This F1 was evaporated using a speed vac (Savant 
SC100), and kept under nitrogen gas at -20ᵒC. The doses used of F1 in cell culture were 
calculated based on its phenolic content.
103
 
Cell lines  
Cell lines used in this study were obtained from the American Type Culture Collection 
(ATCC, Manassas, VA). The estrogen-positive human breast cancer cells MCF-7, were 
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cultured using Dulbecco‟s modified Eagle‟s medium (DMEM) high glucose, L-
glutamine, 25 mM HEPES buffer, pyridoxine hydrochloride, without sodium pyruvate 
and without phenol red, supplemented with 5 mL insulin (1 mg/mL), 10% (v/v) fetal 
bovine serum (FBS) and 1% penicillin-streptomycin antibiotic mix.The estrogen 
receptor-negative MDA-MB-453 human breast cancer cell line, was cultured using 
Dulbecco‟s modified Eagle‟s medium (DMEM) with L-glutamine, 4.5 g/L glucose and 
without sodium pyruvate and supplemented with 10% (v/v) (FBS) and 1% streptomycin-
penicillin antibiotic mix. The breast epithelial cells MCF-10A, were cultured in 
Dulbecco‟s modified Eagle‟s medium/F12 (DME/F12) supplemented with 5% (v/v) fetal 
bovine serum (FBS), 1% streptomycin-penicillin antibiotic mix, 1mL EGF (10µg/mL), 5 
mL insulin (1 mg/mL), 250 µl hydrocortisone (1 mg/mL), and 20 µL cholera toxin. 
Culture mediums were supplied by Invitrogen (Gibco™, Invitrogen Corp., Grand Island, 
NY). Cells were maintained at 37 ºC with a humidified 5% CO2 atmosphere. 
Cell proliferation 
The concentration to inhibit the cell growth by 50% (IC50) was established with an 
electronic cell counter (Z1™ Series, Beckman Coulter, Inc). Cells were seeded (1.5 x 104 
onto a 24-well plate) and incubated for 24 h to allow cell attachment before exposure to 
varying concentrations of extracts. A pretreatment number of cells (0-time value) was 
established and medium was replaced containing the F1, chlorogenic acid or neo-
chlorogenic acid dissolved in DMSO.All cultures contained 1 mL/L each of solvent. Each 
experiment was carried out in triplicate, and the results were expressed as means ± SD. 
The difference in number of cells between final incubation time (72 h) and 0-time 
represents net growth. 
Western-blot analysis 
Cells were seeded (0.5 x 10
6
) onto a 6-well culture plate in 10% FBS/DMEM and 
incubated for 12 h to allow cell attachment. After 12 h of incubation in a serum-free 
media, cells were treated with F1, chlorogenic acid or neo-chlorogenic acid dissolved in 
DMSO for different times/doses. Media was discarded and cells were washed with PBS 
and then removed by scraping using PBS. After centrifugation, cells were lysed with non-
denaturing buffer (10 mM Tris-HCl, 10 mM NaH2PO4, 130 mM NaCl, 1% (v/v) Triton 
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X-100, 10 mM sodium pyrophosphate, (pH 7.5), and 1% proteinase inhibitor cocktail 
(Sigma,-Aldrich) for 30 min in ice. Solid cellular debris was removed by centrifugation at 
10,000 rpm for 10 min at 4ᵒC. The supernatant was collected and stored at -80ᵒC. Protein 
content was determined using the Bradford assay. For each lane sixty g of protein was 
diluted with Laemmli‟s loading buffer, boiled, and loaded on an acrylamide gel (10%, or 
15%) and subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis at 100 
V for ̴ 2 h. Proteins were transferred by wet blotting onto 0.2 µm PVDF membrane (Bio-
Rad, Hercules, CA). Membranes were blocked using 5% milk in TPBS for 30 min and 
incubated with primary antibody either in fresh 5% milk or 3% bovine serum albumin in 
TPBS overnight at 4ᵒC with gentle shaking and incubated with the secondary antibody 
(1:5000) in 5% milk TPBS for 2 h. The concentrations of the primary antibodies ranged 
from 1:250 to 1:1000. Reactive bands were visualized with an enhanced 
chemiluminescence (ECL) Plus system (Amersham Corp., Arlington Heights, IL) after 5 
min of incubation.  
Immunofluorescence analysis and phase contrast microscopy 
Cell seeded on coverslips (0.5 x 10
6
) onto a 6-well culture plate were incubated for 12 
h to allow cell attachment. After 12 h of incubation in serum-free media, cells were 
treated with different doses of F1, chlorogenic acid or neo-chlorogenic acid (10 mg/L) 
dissolved in DMSO for 24 h. Monolayers were prepared for immunofluorescence 
analysis by washing them twice with PBS, followed by fixation with 3.8% 
paraformaldehyde, and permeabilization in 0.5% Triton X-100. Blocking was performed 
for 2 hr in PBS containing 5% BSA. Then, primary antibodies (EndoG or AIF) (1:250 
dilution) were applied for 2 h in blocking solution. All subsequent steps were performed 
in the dark. The secondary antibody (Alexa FluorG488 goat anti-rabbit IgG, Invitrogen 
(Carlsbad, Ca.) (1:1000 dilution), was applied in the same way as the primary for 45 min. 
After rinsing with PBS, DAPI (4',6-diamidino-2-phenylindole solution, Invitrogen, 
Molecular Probes (Carlsbad, Ca.) (5µg/mL) was applied for 5 min. Mounting of the 
coverslip was performed with Prolong Gold Antifade reagent, Invitrogen (Carlsbad, Ca.) 
according to the manufacturer‟s instructions. All microscopic images were taken with a 
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Zeiss Axioplan 2 microscope (Carl Zeiss, Thornwood, NY) fitted with an Axiocam 
high152 resolution digital camera and Axiovision 4.1 software. 
Statistical analysis 
Quantitative data represent mean values with the respective standard deviation or 
standard error of the mean corresponding to 3 or more replicates. Data were analyzed by 
one-way analysis of variance (ANOVA) using SPSS version 15.0 (SPSS Inc., Chicago, 
IL). Post-hoc Tukey pairwise comparisons were used (p<0.05). 
 
Results and Discussion 
Cell proliferation 
The net growth of the estrogen independent MDA-MB-435 breast cancer cells was 
preferentially inhibited by F1, chlorogenic and neo-chlorogenic acid over the estrogen 
independent MCF-7 or the epithelial MCF-10A breast cells. The order of potency against 
the three cell lines was MDA-MB-435 > MCF-10A > MCF-7 (Table 4).  
The major active ingredients in F1 seem to be chlorogenic acid and neo-chlorogenic 
acid due to their greater differential effect on cell growth-suppression of the MDA-MB-
435 cell line versus the other breast cell lines as compared to the F1 differential effect. 
Emerging literature reports that plant phytochemicals may induce apoptosis in neoplastic 
cells but not in normal cells.
47-49
 The study of molecular pathways targeted by these 
compounds would provide valuable information for their potential application in cancer 
therapy and chemoprevention.  
 
 
Table 4. Concentrations of phenolic acids from yellow-fleshed Rich Lady (F1) and 
chlorogenic and neo-chlorogenic acids to cause 50% cell-growth inhibition (IC50). 
Cell Line 
  
IC 50 (mg/L) 
MCF-7 MDA-MB-435 MCF-10A 
F1 ̴ 2102 301 ± 10 431 ± 8 
Chlorogenic acid > 60
2
 17
1
 ± 4 > 60
2
 
Neo-chlorogenic 
acid 
> 60
2
 10
1
 ± 3 > 60
2
 
1
Average of three or more independent determinations ± SD. 
2
Average of two 
determinations.  
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Molecular mechanisms behind the anti-proliferative activity of F1, chlorogenic acid 
and neo-chlorogenic acid 
The process of carcinogenesis results from several cell signaling pathways 
inappropriately activated or silenced. Recent studies suggest that the chemopreventive 
effects of phenolic acids may be ascribed to their ability to modulate the components of 
cell signaling pathways.  
The role of RL (F1), chlorogenic and neo-chlorogenic acids on the pro-survival Akt 
pathway 
Akt, also referred to as PKB (Protein Kinase B) or Rac, plays a critical role in 
controlling survival and apoptosis.
123
 We found that treatment with F1, chlorogenic and 
neo-chlorogenic acids exerted different responses on the Akt  pro-survival pathway 
(Figure 10).  
 
 
 
 
Figure 10. Rich Lady (F1) (A), chlorogenic acid (B) and neo-chlorogenic acid (C) 
exert different time-response on the pattern of Akt1 phosphorylation. Cells were 
treated with F1 (30 mg chlorogenic acid equiv./L) (A), chlorogenic acid (17 mg/L) 
(B), or neo-chlorogenic acid (10 mg/L) (C). These doses were established based on 
the IC50 values, control cells (c), cells were cultured with serum free medium for 36 
h. Cell lysates were assessed by western blotting using polyclonal and monoclonal 
antibodies. Total β-actin was detected to show the relatively same amount of protein 
load. The data represent a typical experiment conducted three times with similar 
results. 
 
 
 
Our results indicate that only neo-chlorogenic acid downregulates the Akt1 
phosphorylation; this is consistent with the increase of basal levels of Akt1, whereas 
chlorogenic acid does not target this pathway. This might explain the relatively higher 
potency in dose-dependent cell growth inhibition exerted by neo-chlorogenic acid. Akt is 
C  0.25 0.5 1  2   6    12 24 36 C  0.25 0.5 1    2     6 12 24   36 Time (h)
- Akt
- p-Akt1
- β-actin
C    0.25 0.5  1 2      6  12  24 36
(A) F1 (B) Chlorogenic acid (C) Neo-chlorogenic acid
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a major downstream effector of PI3K (phosphatidylinositol-3 kinase) that regulates 
various biological processes such as cellular growth, differentiation, and survival via 
activating or repressing multiple factors and cofactors.
3
 Mutation and amplification of 
Akt are frequent in breast cancer.
16
 Akt has antiapoptotic effect by phosphorylating and 
inactivating several pro-apoptotic targets, including Bad
124
 and caspase-9.
20
  
In addition, Akt stimulates cellular proliferation by regulating cell cycle control 
proteins,
125
 as well as p38.
126
 However, we did not find changes on the cell cycle kinetics 
upon treatment with eiher F1, chlorogenic acid or neo-chlorogenic acid (data not shown).  
On the other hand, neither treatment with F1 or chlorogenic acid downregulated the 
phospho-Akt, in contrast, F1 seems to exert the opposite effect (Figure 10). This 
highlights the significance of evaluating food extracts instead of pure compounds. The 
overall effects of such compounds on cell responses are the result of interactions of 
bioactive ingredients as they are found in the food matrix. 
Role of RL (F1), chlorogenic and neo-chlorogenic acids on the pro-apoptotic pathways 
A mechanistic “endpoint” or “point of no return” occurs in apoptosis or programmed 
cell death when there is a massive caspase activation, loss of mitochondrial 
transmembrane potential, complete permeabilization of the outer mitochondrial 
membrane or exposure of phosphatidylserine residues that emit “eat me” signals to 
neighboring cells.
22
  
Apoptosis might occur by activation of caspase dependent pathway or alternative 
pathways that may not involve caspase activation. Depending on the origin of the death 
stimulus, apoptosis is also classified as being either extrinsic or intrinsic. 
Role of F1, chlorogenic and neo-chlorogenic acids on the extrinsic apoptotic death 
receptor pathway  
Death ligands have been explored as potential therapeutics in cancer therapy and we 
found that F1, chlorogenic and neo-chlorogenic acids activate caspase-8, which induces 
apoptosis through the extrinsic pathway (Figure 11). 
The extrinsic cell death pathway is initiated upon ligand-receptor interactions at the 
cell surface including FAS ligand-FAS/APO1, TNF-TNF receptors, and TRAIL-TRAIL 
receptors. Upon ligation, the Fas receptor allows the dimerization of caspase-8 
monomers, which is a fundamental activation event in the caspase cascade.
127
 Caspases 
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are the family of proteases that participate in a cascade that is triggered in response to 
proapoptotic signals and culminates in the cleavage of a set of proteins, and disassembly 
of the cell.
128
 
 
 
 
 
Figure 11. Caspase activation by F1, chlorogenic and neo-chlorogenic acids. Cells 
were treated with F1 (30 mg chlorogenic acid equiv./L) (A), chlorogenic acid (17 
mg/L) (B), or neo-chlorogenic acid (10 mg/L) (C). These doses were established 
based on the IC50 values, control cells (c), cells were cultured with serum free 
medium for 36 h. Cell lysates were assessed by western blotting using polyclonal and 
monoclonal antibodies. Total β-actin was detected to show the relatively same 
amount of protein load. The data represent a typical experiment conducted three 
times with similar results. 
 
 
 
The initiators caspase-8 and caspase-9 were activated by the tested compounds at ̴ 0.5 
h after treatment. This was consistent with the activation of the downstream executioner 
caspase-7 and caspase-6. Although most studies indicate that caspase-3 is also activated 
by the initiator caspases,
127
 we did not find caspase-3 activation by any of the compounds 
used in our study (data not shown). In contrast, the executioner caspase-6, which has not 
been extensively studied, seems to play an important role as indicated by its early 
activation. Furthermore, we speculate that chlorogenic and neo-chlorogenic acids work 
synergistically to cause the stronger caspase-6 activation seen in the F1-treated cells. A 
similar pattern for caspase activation has been reported for the chemotherapeutic 
cisplastin, in which caspase-7 and caspase-6, but not caspase-3 were found to be 
transcriptional targets of p53 cisplastin-induced expression.
129
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43 
 
 
 
Caspase-6 and -7 participate in apoptosis as executioner caspases responsible for 
cellular changes that occur during a programmed cell death. They reorganize the 
cytoskeleton, shut down DNA replication and repair, interrupt splicing, destroy DNA, 
disrupt the nuclear structure, induce the cell to display signals that mark it for 
phagocytosis, and disintegrate the cell into apoptotic bodies.
128
  
We found an increase on the Poly (ADP-ribose) polymerase 1 (PARP) fragment 
(89kDa), consistent with the time response for caspase activation. PARP is specifically 
proteolyzed by caspases,
130
 and upon cleavage into its 24kDa and 89kDa fragments, it 
promotes apoptosis by preventing DNA repair-induced survival.
131
 Alternatively PARP is 
linked to the intrinsic apoptotic pathway.
132
 When activated by reactive oxygen species 
(ROS), PARP initiates a nuclear signal that propagates to mitochondria and triggers the 
release of apoptotic inducing factor (AIF), which in turn translocates to the nucleus and 
induces peripheral chromatin condensation, large-scale fragmentation of DNA and cell 
death.
34
  
In addition, the extrinsic pathway targets the intrinsic apoptotic pathway through 
caspase-8 activation. Caspase-8, as initiator can promote the release of cytochrome c 
from the mitochondria, which together with Apaf-1 activates caspase-9. This is mediated 
by its ability to cleave the pro-apoptotic Bcl-2 family member Bid.
133
 Either caspase-8 or 
caspase-9 can trigger the cleavage and activation of downstream executioner caspase-3, -
7 and -6. 
127, 133, 134
  
Role of F1, chlorogenic and neo-chlorogenic acids on the intrinsic apoptotic 
mitochondrial pathway  
Apoptosis through this pathway is regulated by the Bcl-2 family of proteins. They have 
the capacity to regulate the permeability of mitochondrial membranes to ions and 
proteins.
26
 Proapoptotic members of the Bcl-2 family, especially Bax have the ability to 
form channels and to regulate preexisting channels, whereas antiapoptotic members of 
this family have the opposite effect.
26
 
We found that F1, chlorogenic and neo-chlorogenic acids trigger apoptosis through 
modulation of Bcl-2 family of proteins that activated the pro-apoptotic Bax with no 
changes on levels of antiapoptotic Bcl-2, thus the ratio Bax/Bcl-2 favors apoptosis 
(Figure 9). However, the time-response for Bax activation differs among the tested 
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compounds. Neo-chlorogenic acid and F1, exerted an early activation of Bax and 
cytochrome c release. This may explain the higher potency of neo-chlorogenic acid, 
therefore the activation of Bax and cytochrome c release time-response exerted by F1 
may result mainly due to neo-chlorogenic acid induction, since both showed similar time-
response (Figure 12).  
Several studies have demonstrated the key role of Bax in counteracting the death 
repressor activity of Bcl-2 and how the ratio of Bcl-2 to Bax determines survival or 
death.
135
 
Likewise, the activation of Bim, which interacts with diverse antiapoptotic Bcl-2 
family members and promotes apoptosis, seems to be induced by the chlorogenic acid 
component in F1 (Figure 12). Bim has been related to death stimuli activation and acts as 
a 'death ligand' which can neutralize certain members of the pro-survival Bcl-2 sub-
family.
136
 The proapoptotic Bim mediates the induction of apoptosis following 
cytoskeletal perturbations caused by the disturbance on cell adhesion, intracellular 
transport, or stimulation by growth factors.
137, 138
 Once dissociated from the cytoskeleton, 
Bim translocates to the mitochondria where it binds to Bcl-2 and Bcl-xL and sequesters 
them from proapoptotic proteins such as Bax and Bak. The chemical structure of 
chlorogenic acid, could represent a specific microtubule-targeting compound for potential 
application in metastatic cancer, where cell motility and adhesion are critical.
138
 
Unlike chlorogenic and neo-chlorogenic acid treated cells, the anti-apoptotic Bcl-2 in 
F1-treated cells varied through time with up- and down-regulations. Such pattern may be 
the result of differences between chlorogenic and neo-chlorogenic acids in the time-
response and strength of activation of pro-apoptotic Bcl-2 family members. In general, 
our results show the up-regulation of proapoptotic Bcl-2 family of proteins and the 
subsequent efflux of cytochrome c from mitochondria (Figure 12).  
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Figure 12. Treatment of MDA-MB-435 cells with RL (F1), chlorogenic acid and neo-
chlorogenic acid activated pro-apoptotic Bcl-2 family members and induced 
cytochrome c release from mitochondria. Cells were treated with F1 (30 mg 
chlorogenic acid equiv./L) (A), chlorogenic acid (17 mg/L) (B), or neo-chlorogenic 
acid (10 mg/L) (C). These doses were established based on the IC50 values, control 
cells (c), cells were cultured with serum free medium for 36 h. Cell lysates were 
assessed by western blotting using polyclonal and monoclonal antibodies. Total β-
actin was detected to show the relatively same amount of protein load. The data 
represent a typical experiment conducted three times with similar results. 
 
 
 
This intrinsic apoptotic pathway has been shown to be activated by natural compounds 
in response to a wide range of stimuli including stress that target the upstream activation 
of mitogen activated protein kinase (MAPK) pathway.
13, 14, 139
 Likewise, several studies 
have shown the role of MAPKs on the modulation of Bcl-2 family of proteins that control 
the mitochondrial mediated apoptotic pathway.
140,120, 141, 142
 
Role of F1, chlorogenic and neo-chlorogenic acids on the MAPK pathway  
The mitogen-activated protein kinases (MAPKs) pathway is frequently altered in a 
variety of human cancers and modulation of this pathway by dietary compounds may 
provide novel strategies for prevention and treatment of cancer.
143
 
MAPKs are the family of kinases that transduce signals from the cell membrane to the 
nucleus in response to stress, growth factors, cytokines, and other extracellular 
stimulus.
13
  
We found that F1 and its active compounds chlorogenic and neo-chlorogenic acids 
target the MAPK pathway by activating the ERK1/2 and p38, but not the JNK  (data not 
shown) in a time and dose dependent manner, though the pattern of activation for 
ERK1/2 and p38 varied (Figure 13). 
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Figure 13. RL phenolic acid fraction F1, chlorogenic acid and neo-chlorogenic acid 
activate MEK/ERK signaling pathway. (Top panel) MDA-MB-435 cells were treated 
for 0.25, 0.30, 1, 2 6, 12, 24 and 36 h, with F1 (30 mg chlorogenic acid equiv./L) (A), 
chlorogenic acid (17 mg/L) (B), or neo-chlorogenic acid (10 mg/L) (C). These doses 
were established based on the IC50 values, control cells (C), cells were cultured with 
serum free medium for 36 h. (Lower panel) MDA-MB-435 cells were treated with 
different doses of F1 (D), chlorogenic acid (E), and neo-chlorogenic acid (F). All 
treatments received the same volume of vehicle (DMSO). Positive control (+C) cells 
received medium containing 10% FBS 6h before harvesting. Cell lysates were 
assessed by western blotting using polyclonal and monoclonal antibodies. Total β-
actin was detected to show the same amount of protein load. The data represent a 
typical experiment conducted three times with similar results. 
 
 
 
The ERK1/2 was phosphorylated by F1, chlorogenic and neo-chlorogenic acids in a 
similar time-response. A strong and early activation within 1h of treatment was followed 
by a decrease at 2h and the up-regulation cycle was repeated at ̴ 6h, ̴ 24h, and ̴ 36h. In 
contrast, the ERK1/2 level of protein differs among the tested compounds, F1 and 
chlorogenic acid treatments did not alter the basal levels of ERK1/2, whereas in cells 
treated with neo-chlorogenic acid, ERK1/2 decreased in harmony to the upregulation of 
phospho-ERK1/2 after 12h. This suggests that neo-chlorogenic acid may exert a stronger 
ERK1/2 activation, compared to F1 and chlorogenic acid. The ERK1/2 is a well-
characterized MAPK family member generally activated in response to growth stimuli. 
However, the ERK1/2 pro-proliferation effect is likely to occur upon a short duration of 
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the upstream MEK1/2-MAPK cascade as exerted by growth factors. In contrast, an early 
and sustained activation of MEK1/2-MAPK has shown to trigger cellular apoptosis.
14
 In 
addition, it has been reported that activation of ERK1/2 pathway may commit the cell to 
apoptosis when it happens before the activation of p38 and JNK.
144
 Previous studies have 
reported the role of ERK1/2 activation in the anti-proliferative and pro-apoptotic effects 
of dietary phytochemicals.
139, 145
 Oxidants may act usurping growth factor receptor 
signaling.
146, 147
 Studies have shown that many antioxidants can also exhibit prooxidant 
behavior under certain conditions,
148
 thus the phenolic acids used in our study would be 
acting as pro-oxidants.
148, 149
  
Unlike ERK1/2, whose role in the MAPK signaling pathway is controversial, p38 is 
known to be simultaneously activated in response to a variety of cellular and 
environmental stresses that triggers to apoptosis.
13, 150-152
 We found p38 MAPK signaling 
was activated upon treatment with F1, chlorogenic or neo-chlorogenic acid. Although 
basal levels of p38 increased upon treatment, the time-response and strength varied 
among the compounds tested. The F1 exerted an increase on p38 levels at ̴ 1h of 
treatment and the activation by phosphorylation occurred relatively late , after ̴ 12h. 
Chlorogenic acid and neo-chlorogenic acid on the other hand, exerted an early expression 
of p38, at  ̴  0.25h, and it was consistent to the prolonged p38 activation by 
phosphorylation up to 36h. This may indicate that both of them triggered p38 activation 
at such magnitude that the basal levels of p38 decreased after ̴ 2-6h. On the other hand, 
even though chlorogenic and neo-chlorogenic acid have been identified as the active 
ingredients in F1, the effect of both phenolic acids in F1 or the presence of other phenolic 
acids in this fraction may be antagonist for the activation of p38.  
We also found that c-Jun was phosphorylated upon treatment with F1, chlorogenic or 
neo-chlorogenic acids in a time and dose-dependent manner. The role of c-Jun has been 
reported to be critical in the induction of apoptosis on MDA-MB-435 cells as a 
downstream component of three interrelated apoptotic triggering pathways (involving c-
Jun amino-terminal kinase (JNK), TGF-β, and Fas.153 Additionally, the c-Jun 
phosphorylation and activation may play an important role in induction of apoptosis on 
multidrug resistance tumor cells.
154
 The sustained ERK1/2 activation was found to be 
upstream of c-Jun phosphorylation (Figure 14). This is in agreement with previous 
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studies showing the same response of ERK sustained activation on the activation of AP-1 
(activating protein-1), consisting of either homo or heterodimers of the Jun and Fos 
families.
155
 The modulation of AP-1 has been proposed as a promising strategy to prevent 
cancer due its target genes that may control growth, apoptosis, oncogene-induced 
transformation, and invasiveness.
3
  
Role of F1, chlorogenic acid and neo-chlorogenic acid on the crosstalk extrinsic-
intrinsic apoptotic pathways 
We assessed the nuclear relocalization of AIF and EndoG in cells treated with different 
doses of F1, chlorogenic acid and neo-chlorogenic acid by immunofluorescence 
microscopy (Figure 15). By using doses equivalent to the IC50 value, this means under 
similar potency on cell growth-inhibition, we were able to compare the extent of 
activation of this pathway.  
As discussed previously, mitochondrial outer-membrane permeabilization plays a 
critical role in apoptosis induction mediated by the release of pro-apoptotic proteins 
cytochrome c, Smac/Diablo and HtrA2/Omi, endonuclease G (EndoG) and apoptotic 
inducing factor (AIF). However the EndoG and AIF nuclear translocation have been 
defined as a “caspase-dependent” mitochondria-initiated apoptotic pathway, conserved 
between mammals and nematodes.
156
 This was shown when the broad spectrum caspase 
inhibitor zVAD-fmk prevented the release of EndoG and AIF but did not affect the efflux 
of the other mitochondrial pro-apoptotic proteins when used together with pro-apoptotic 
Bax/Bak drugs.
156
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Figure 14. Inhibition of MEK1/2, the upstream activator of ERK1/2 blocks ERK1/2 activation and decreases c-Jun 
phosphorylation. MDA-MB-435 cells were treated with 30mg chlorogenic acid equiv./L of RL phenolic acids fraction F1 (A), 
17 mg/L of chlorogenic acid (B) or 10 mg/L of neo-chlorogenic acid (C) for 0.5, 1, 2, 6, 12, 24 and 36h, 10µM of U0126 was used 
for MEK1/2 inhibition, control cells (C) were incubated for 36h with same volume of DMSO as treated cells. Cell lysates were 
assessed    by western blotting.Total β-actin was determined to show the same of protein load for all treatments. 
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Figure 15. Phenolic acids fraction F1 (A), chlorogenic acid (B) and neo-chlorogenic acid (C) target apoptosis through nuclear 
translocation of AIF and EndoG from mitochondria. The nucleus is stained blue with DAPI that binds to DNA and AIF and 
EndoG were tagged with green fluorescent secondary antibody. The images were captured using an Axiocam high152 
resolution digital camera. The green brightness provides an estimated level of AIF or EndoG in nucleus. These experiments 
were repeated for 3 times and the same observations were obtained. 
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Our results indicate that AIF and EndoG play a critical role on the pro-apoptotic effect 
of F1, as shown for the dose-response increasing signal of both proteins in the nucleus. In 
contrast, chlorogenic and neo-chlorogenic acids seem to trigger apoptosis through nuclear 
translocation of AIF and EndoG to a lesser extent. As discussed previously, it is possible 
that the release of AIF and EndoG may be dependent on caspase activation as well.
156
   
So far, we have identified key components of the apoptotic machinery that are being 
triggered by RL phenolic acid fraction F1 and its active ingredients chlorogenic acid and 
neo-chlorogenic acid. Additionally, evidence of a crosstalk among the activated 
intracellular pathways has been documented. In general, such evidence includes but is not 
limited to: i) The activation of pro-caspase-9 was found to be regulated by Akt-
phosphorylation.
124
 ii) Caspase-7 activation was shown to be crucial on the mitochondrial 
events of apoptosis including AIF and cytochrome c release.
157
 iii) Fas activation of p38 
MAPK correlated with the onset of apoptosis.
158
 iv) Fas-induced apoptosis stimulates the 
downstream effectors of receptor tyrosine kinases such as ERK1 levels and ERK1 
phosphorylation.
159
 
Therefore, we used specific inhibitors to block activation of ERK1/2 (U0126), p38 (SB 
202190) or the caspase cascade (zVAD-fmk) in order to evaluate the degree of 
contribution of each one of the activated cell signaling pathways on the activation of the 
intrinsic mitochondrial pathway. Bax was used as a marker for mitochondrial 
permeabilization targeted pathway (Figure 16).  
The activation of p38, ERK1/2, and caspase exerts varying effects on the activation of 
Bax activation. In F1 treated cells, Bax activation seems to be uniformly down-regulated 
when ERK1/2 and p38 activation is inhibited, whereas cleavage of caspase does not 
contribute to Bax activation. In chlorogenic acid treated cells, ERK1/2 and caspase 
activation contribute to Bax activation. In contrast, inhibition of p38 phosphorylation did 
not affect the level of activated Bax. Finally, in neo-chlorogenic acid treated cells p38 
and caspase inhibition in descending targeted the Bax down-regulation, in contrast to the 
inhibition of ERK1/2, which did not affect the extent of Bax activation.  
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Figure 16. Bax activation on MDA-MB-435 cells upon activation of different cell 
signaling pathways. Cells were treated with RL, F1 (30mg chlorogenic acid 
equiv./L(A), chlorogenic acid (17mg/L) (B) or neo-chlorogenic acid (10mg/L) (C) 
with and without inhibitors for ERK1/2 phosphorylation (U0126), p38 
phosphorylation (SB 202190) or caspase activation (zVAD-fmk) and blocked with 
anti-Bax. Tested compounds were dissolved in DMSO.  
 
 
 
The antiproliferative and pro-apoptotic effect exerted by these phenolic acids on 
MDA-MB-435 breast cancer cells are likely to be the sum of several cell signal 
transduction pathways. The proposed model that explains the elucidated cell signaling 
pathways being targeted by RL phenolic acid fraction F1, chlorogenic and neo-
chlorogenic acids is shown in Figure 17. We hypothesize that these compounds are 
modulating cellular responses to stress and a crosstalk among the activated pathways may 
contribute to maximize effectiveness and minimize toxicity on non-cancerous cells.  
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Figure 17. Molecular pathways targeted by RL phenolic acid fraction F1, 
chlorogenic acid and neo-chlorogenic acid on MDA-MB-435 metastatic breast 
cancer cells. 
 
 
 
 
Conclusion 
Selected phenolic acid fraction F1 from yellow-fleshed peach variety Rich Lady (RL) 
and its active ingredients chlorogenic and neo-chlorogenic acids target several cell 
signaling pathways that decrease cell proliferation and induce apoptosis on the MDA-
MB-435 estrogen receptor-negative breast cancer cells.  
Our study on cell growth-inhibition and molecular mechanisms showed neo-
chlorogenic acid as the most potent among the tested compounds. The higher growth-
inhibition activity exerted by neo-chlorogenic acid may be related to its unique ability to 
downregulate the Akt cell survival pathway. However, this effect was masked in F1, 
probably due antagonist interactions among its components on cell membrane receptors 
upstream of this pro-survival pathway.  
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Induction of apoptosis exerted by the tested compounds involved activation of 
extrinsic and intrinsic pro-apoptotic pathways. The extrinsic pathway was activated by 
targeting the death receptor pathway, which activates the initiator caspase-8 and the 
downstream effectors caspase-6 and -7. The intrinsic mitochondrial apoptotic pathway 
was triggered by activation of the pro-apoptotic Bax, and increasing the ratio Bax/Bcl-2 
in favor of outer mitochondrial membrane permeabilization. Although neo-chlorogenic 
acid was more potent in cell growth-suppression, it failed to activate Bim, another pro-
apoptotic Bcl-2 family member. Both the caspase activation and MAPK activation 
mediated by ERK1/2 and p38 phosphorylation, were shown to play important roles on 
activation of pro-apoptotic Bax, except on chlorogenic acid treated cells, where p38 
phosphorylation did not contribute to Bax activation. Mitochondria permeabilization 
resulted in the release of the pro-apoptotic proteins AIF, EndoG and cytochrome c. In the 
cytosol, cytochrome c promotes the formation of the apoptosome, and activates caspase-
9, whereas AIF and EndoG shuttle to the nucleous and induces DNA fragmentation and 
cell death.  
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CHAPTER IV 
APOPTOSIS INDUCTION OF PHENOLIC ACID FRACTION FROM RED-
FLESH PEACH BY00P6653 ON MDA-MB-435 CELLS IS MEDIATED BY 
MITOCHONDRIAL PATHWAY THROUGH MAPK-ERK1/2 ACTIVATION 
 
Synopsis 
Phenolic compounds in fruits and vegetables have shown to possess chemopreventive 
and therapeutic activities by modulating cell signaling pathways and inducing apoptosis 
on malignant cells. This study investigated the molecular mechanisms involved in 
anticancer activity of a phenolic acid rich fraction (F1) extracted from the BY00P6653 
red-flesh peach genotype on the estrogen receptor negative MDA-MB-435 breast cancer 
cells. The main phenolics identified in F1 by HPLC were chlorogenic acid, a chlorogenic 
acid derivative and traces of cyanidin 3-β-glucoside. F1 caused a dose-dependent 
decrease of cell viability (IC50 = 150 mg chlorogenic acid equiv./L) and activated the 
mitogen-activated protein kinase (MAPK) pathway through ERK1/2 sustained 
phosphorylation. Our studies using the MEK1/2 inhibitor (an upstream kinase in ERK1/2 
signaling pathway) showed that the intrinsic apoptotic mitochondrial pathway was 
downstream of ERK1/2 activation. The cascade of events triggered by F1 was ERK1/2 
phosphorylation  Bax/Bak activation   mitochondria membrane permeabilization  
release of proapoptotic proteins: cytochrome c, apoptotic inducing factor (AIF) and 
endonuclease G (EndoG). Even though the caspase apoptotic pathway was activated by 
both cytochrome c release and a delayed activation of death receptor pathway, the 
intrinsic apoptotic pathway appears to be critical for a F1-induction of caspase-
independent apoptosis as assessed when the pan caspase inhibitor (zVAD-fmk) was used. 
These results suggest that peach phenolics may have potential in therapy and 
chemoprevention of metastatic breast cancer. 
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Introduction 
Breast cancer is the second leading cause of cancer death in women in the US. The 
American Cancer Society has estimated that there will be 182,460 new cases of invasive 
breast cancer among women in the US during 2008.
1
 Whereas localized breast cancer can 
be cured by surgery, the high mortality rate associated with breast cancer is due to a 
propensity of the tumor to metastasize when the primary tumor is small or 
undetectable.
160
 
Multiple factors contribute to the development of human breast cancer of which 
environmental factors, especially diet, appear to have a great effect. While consumption 
of a high-fat diet as occurs in industrialized countries may contribute to increase the risk 
of breast cancer, 
161
 a diet rich in fruits and vegetables is one of the factors that may 
decrease breast cancer risk. 
162
 Moreover, some studies have reported greater survival 
after breast cancer in physically active women with reduced dietary fat and increased 
fiber, vegetable, fruit, and other nutrient intakes associated with a plant-based diet. 
163, 164
  
The process of carcinogenesis involves several cell signaling pathways inappropriately 
activated or silenced. Research in the signal transduction area has shown that this 
mechanism is the crucial communication route between membrane-bound proteins and 
the nucleus. Even though several studies have identified specific cell signaling pathways 
targeted by natural compounds, 
45, 121
 there are still many unknowns and the overall 
effects of these compounds on breast cancer cells may result from a crosstalk among 
them.  A cell signaling pathway that frequently seems to be altered in a variety of human 
cancers is the mitogen-activated protein kinases (MAPKs) pathway. MAPKs are the 
family of kinases that transduce signals from the cell membrane to the nucleus in 
response to a wide range of stimuli including stress. 
13
  The MAPK signaling pathways 
modulate gene expression, mitosis, proliferation, motility, metabolism, and programmed 
death or apoptosis. MAPKs consist of three family members: the extracellular signal-
regulated kinase ERK1/2, c–Jun NH2-terminal kinase (JNK); and the p38-MAPK. The 
ERK1/2 is generally activated in response to growth stimuli whereas JNK and p38-
MAPK are known to be simultaneously activated in response to a variety of cellular and 
environmental stresses that triggers to apoptosis.
13
 Although most studies relate ERK 
activation to cell proliferation, others show that activation of ERK cascade promotes 
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contrary cellular responses that vary upon cellular context,
14
 including cell proliferation, 
cycle arrest, differentiation, senescence, or apoptosis.
15
 
In general, apoptosis may occur through the activation of intrinsic mitochondria 
pathway or extrinsic death receptor pathway.
23
 The mitochondria pathway is controlled 
by Bcl-2 family of proteins which regulate the permeability of mitochondria membranes. 
The proapoptotic members of the Bcl-2 family, Bax, Bak and Bid form channels or 
regulate preexisting channels in the mitochondrial membrane, whereas the antiapoptotic 
Bcl-2 and Bcl-xL have the opposite effects on membrane channel formation.
26
 Bak is 
constitutively associated with the mitochondria,
27
 unlike Bax, which exists as a monomer 
either in the cytosol or loosely attached to the outer mitochondrial membrane. Upon 
induction of apoptosis, the cytosolic Bax translocates to the mitochondria, simultaneously 
with this translocation, Bax oligomerizes into large complexes.
28, 29
 Like Bax, during 
apoptosis, Bak homo-oligomerizes and both have a degree of functional cooperation 
during the channel formation and trigger cytochrome c release from the mitochondria.
30
 
The antiapoptotic proteins, Bcl-xL and Bcl-2, are located in the outer mitochondrial 
membrane and blocks cytochrome c release that follows the activation of Bax and Bak, 
thus preventing it from catalyzing caspase activation.
26, 31
 The activation of the death 
receptor pathway is mediated by Fas-signaling and induced by ligation of the Fas 
receptors by Fas-ligands or anti-Fas antibodies. When activated, the Fas/Fas-L receptor 
triggers the recruitment of  caspase-8 to the death-inducing signaling complex.
133
 Once 
caspase-8 is activated, it has the ability to activate the executioner caspases 3, 6 and 7.
127
 
In addition this extrinsic pathway can trigger the mitochondrial pathway through 
cleavage of Bid.
165
which is further post translationally modified 
166
 to interact and 
activate Bax or Bak.
26
 The release of cytochrome c, as a cofactor, is a requirement for 
caspase-9 activation,
128
 which is mediated by the formation of the apoptosome, a protein 
complex in which procaspase-9 is activated into its active form.
23, 133
 The active caspase-
9 then, may activate downstream executioner caspases.
127
 Therefore, this extrinsic 
pathway works via a crosstalk with the intrinsic mitochondrial pathway.
134, 167
 
Plant extracts induce apoptosis in cancer cells by targeting cell signaling pathways that 
inhibit, reverse or retard tumorigenesis.
45, 143
 In this context, the use of plant extracts 
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containing a mixture of phytochemicals is being intensely researched for their  
chemopreventive effects.  
Peaches contain hydroxycinnamates (chlorogenic acid, neochlorogenic acid), flavan 3-
ols (catechin, epicatechin) and flavonols (quercetin derivatives).
51
  Many of these 
phenolics act as antioxidants,
119, 168
 antimutagenics,
169, 170
  and anticarcinogenics in vitro 
and in vivo.
68, 73-75
 Specifically chlorogenic acid and caffeic acid derivatives have been 
subject of many health related claims.
60-63, 65, 66, 70, 171
 Likewise, emerging literature 
reports different molecular targets in the chemopreventive effects of caffeoylquinic acid 
derivatives which differ upon cell context.
68, 122
  
Peach varieties with enhanced functional properties (high anti oxidant activity and high 
phenolic content) have been reported.
101, 102
 Our goal is to understand the molecular 
mechanisms involved in anticancer activity exerted by a fraction rich in phenolic acids 
(F1) extracted from BY00P6653 red-flesh peach genotype. 
 
Materials and Methods 
Chemicals 
The Folin-Ciocalteu reagent, dimethyl sulfoxide (DMSO) and N-acetyl cysteine 
(NAC) were purchased from Fisher Scientific (Pittsburgh, PA). Ethanol, methanol and 
ethyl acetate were purchased from VWR International (Bristol, CT). Chlorogenic acid 
was obtained from Sigma-Aldrich (St Louis, MO). The general caspase inhibitor zVAD-
fmk was purchased from BD Bioscience (San Jose, CA). Antibodies for pERK, 
cytochrome c, cleaved caspase-8, -9 and -3 were purchased from Cell Signaling 
Technology Inc. (Beverly, MA), those for p-c-jun, ERK1/2, Bcl-xL, Bax and AIF were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA), and antibodies for  Endo G 
was purchased from Prosci (Poway, CA). MEK1/2 inhibitor (U0126) was used for 
ERK1/2 inhibition (cell signaling Technology, Beverly, MA). 
Plant material 
The red-fleshed peach selection, BY00P6653, obtained from W. R. Okie who heads 
the Peach Breeding Program at USDA-ARS (SE Fruit & Nut Research Lab, Byron, GA) 
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was used for this study. Fruits were collected at the mature firm stage, sent by overnight 
delivery, and stored at 2-4°C (less than 5 days) until the pits were removed and the fruits 
were frozen and kept at -20°C until use. 
Extraction of phenolic acid rich fraction (F1) 
100 g of frozen fruit (flesh plus skin) was blended with 300 mL of methanol and left at 
4°C overnight. The methanolic extract was filtered through whatman #1 filter paper and 
the methanol evaporated at 45°C using a rotavapor (Büchi, Switzerland). Phenolic acids 
(F1) were isolated by solid phase extraction (SPE) using C18 cartridges 
104
. Briefly, the 
aqueous extract was adjusted to pH 7.0 with 5 N NaOH. The extract was loaded in SEP 
Pack C18 cartridge previously conditioned to pH 7.0 with 50 mL of 100% methanol and 
50 mL of nanopure water (pH 7.0). The neutral phenolics were absorbed in the cartridge 
while the phenolic acids were not. The cartridge was washed with 50 mL of water pH 
7.0. The water from the wash was combined with the phenolics that were not adsorbed in 
the cartridge and adjusted to pH 2.0. This mixture of compounds was loaded into a 
second cartridge previously conditioned at pH 2.0 with 50 mL 100% methanol and 50 
mL nanopure water pH 2.0. Phenolic acids bound to the matrix of the second cartridge 
(F1) were later eluted with 50 mL 100% methanol. This F1 was evaporated using a speed 
vac (Savant SC100) and kept under nitrogen gas at -20 ᵒC for use in cell culture.  
HPLC analysis of phenolic acids present in F1  
Phenolic acids in F1 were analyzed using a Waters (Milford, MA, USA) HPLC 
system. An AtlantisTM C18 5 µm, 4.6 mm x 150 mm column and a 4.6 mm x 20 mm 
guard column was used for the separation of phenolic compounds. The mobile phase was 
composed of solvent A (nanopure water adjusted to pH= 2.3 with 2N HCl) and solvent B 
(acetonitrile HPLC grade). The elution was as follows: isocratic conditions from 0-5 min 
with 85% A and 15% B. Gradient conditions from minute 5 to 30 starting with 85% A 
and ending with 0%, and starting with 15% B and ending with 100%. Then, isocratic 
conditions from minute 30 to minute 35 with 0% A and 100% B. The flow rate was 1 
mL/min and 20 µL of sample was injected.
105
 F1 was also analyzed by HPLC after acid 
hydrolysis with HCl 4N at 100° for 45 min. After cooling, the solution was filtered 
through a 0.2µm PTFE filter and analyzed by HPLC. 
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Cell lines  
The MDA-MB-435 estrogen receptor negative breast cancer cells were purchased from 
the American Type Culture Collection (ATCC, Manassas, VA) and maintained as 
recommended. MDA-MB-435 were cultured using Dulbecco‟s modified Eagle‟s medium 
(DMEM), with L-glutamine and 4.5 g/L glucose without sodium pyruvate, and 
supplemented with 10% (v/v) fetal bovine serum (FBS), 1% penicillin-streptomycin 
antibiotic mix. Cells were maintained at 37 ºC with a humidified 5% CO2 atmosphere. 
Cell viability 
Cell viability was measured by using the MTT [3-(4,5-dimethylthiazolyl-2)-2,5-
diphenyltetrazolium bromide] assay.
172
 Cells were seeded at a density of 7,000 cells per 
well in a 96-well plate and incubated for 24 h to allow cell attachment. The medium was 
decanted from each well, and 0.1 mL of fresh medium containing the F1 fraction 
dissolved in DMSO was added at concentrations based on total phenolic content 
measured spectrometrically by Folin-Ciocalteu colorimetric method 
103
 and expressed as 
mg of chlorogenic acid equiv./L, all cultures contained 1 mL/L each of DMSO. After a 
24h incubation period, the culture medium was removed and cells washed with phosphate 
buffer solution (PBS); 100 µL of MTT (5 mg/ml) were added per well and incubated for 
1 h at 37°C. After incubation, MTT was aspirated and 100 µL of DMSO was added to 
lyse the cells and dissolve the blue formazan crystals. Cell viability was calculated 
according to the following equation.  
Cell viability (%) = 100x
mediumtheofODsamplewithoutculturecelltheofOD
mediumtheofODsamplewithculturecellofOD








 
OD is the optical density measured by the spectrophotometer with 555 excitation and 520 
emission filters.  
The role of caspase activation on cell viability was assessed by using the broad 
spectrum caspase inhibitor  zVAD-fmk that prevents apoptotic cell death mediated by 
caspase activation. Vitamin E succinate (VES) (Sigma-Aldrich, St Louis, MO) was used 
as a positive control.  
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Western-blot analysis 
Cells were seeded (0.5 x 10
6
) onto a 6-well culture plate in 10% FBS/DMEM and 
incubated for 12 h to allow cell attachment. After 12 h of incubation in serum-free media, 
cells were treated with F1 dissolved in DMSO for different times or at different doses. 
Media was discarded and cells were washed with PBS and then removed by scraping 
using PBS. After centrifugation, cells were lysed with non-denaturing buffer (10 mM 
Tris-HCl, 10 mM NaH2PO4, 130 mM NaCl, 1% (v/v) Triton X-100, 10 mM sodium 
pyrophosphate, (pH 7.5), and 1% proteinase inhibitor cocktail (Sigma,-Aldrich)) for 15 
min in ice. Solid cellular debris was removed by centrifugation at 10,000 rpm for 10 min 
at 4ᵒC. The supernatant was collected and stored at -80ᵒC. Protein content was 
determined using the Bradford assay. For each lane sixty g of protein was diluted with 
Laemmli‟s loading buffer, boiled, and loaded on acrylamide gel (10%, or 15%) and 
subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis at 100V for  ̴ 2 h. 
Proteins were transferred by wet blotting onto 0.2 µm PVDF membrane (Bio-Rad, 
Hercules, CA). Membranes were blocked using 5% milk in TPBS for 30 min and 
incubated with primary antibody either in fresh 5% milk or 3% bovine serum albumin in 
TPBS overnight at 4ᵒC with gentle shaking and incubated with the secondary antibody 
(1:5000) in 5% milk TPBS for 2 h. The concentrations of the primary antibodies ranged 
from 1:250 to 1:5000. Reactive bands were visualized with an enhanced 
chemiluminescence (ECL) Plus system (Amersham Corp., Arlington Heights, IL) after 5 
min of incubation.  
Statistical analysis 
Quantitative data represent mean values with the respective standard deviation or 
standard error of the mean corresponding to 3 or more replicates. Data were analyzed by 
one-way analysis of variance (ANOVA) using SPSS version 15.0 (SPSS Inc., Chicago, 
IL). Post-hoc Tukey pairwise comparisons were used (p<0.05). 
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Results and Discussion 
Phenolic profile of F1 
Comparison of retention times and UV-visible spectral data of the chromatographic 
profiles of F1 with known standards revealed the presence of chlorogenic acid (peak 1, 
RT= 5.8min), chlorogenic acid derivative (peak 1‟, RT= 4.2min) and cyanidin glucoside 
in very low concentration that almost co-eluted with peak 1 (peak 2‟, RT= 5.4 min) 
(Figure 18-A). After acid hydrolysis (Figure 18-B), the ester bond between the caffeic 
and quinic acid components within chlorogenic acid is broken and caffeic acid is 
released. Thus, peaks 1 and 1‟ were converted into peak 3 (caffeic acid) (RT= 8.9 min) 
and a less polar caffeic acid derivative with same spectrum but different retention time, 
probably with an additional methyl group or a more hydrophobic group since it came out 
~10 min after the caffeic acid standard on a C18 column (peak 3‟, RT= 18.4min). When 
analyzed the HPLC profile at 520 nm (Figure 18-B1), we identified the aglycon cyanidin 
as product from acid hydrolysis of cyanidin 3-glucoside (peak 2, RT=14.9min).  
 
 
 
 
Figure 18. HPLC-DAD chromatographic profile of F1. Spectrum at 280nm before 
(A) and after acid hydrolysis (B). Spectrum at 520nm (B1). 1= chlorogenic acid, 1’= 
chlorogenic acid derivative, 2= cyanidin, 2’ = cyanidin glycoside, 3= caffeic acid, 3’= 
caffeic acid derivative. 
 
 
 
Cell viability 
The cell viability of MDA-MB-435 breast cancer cells decreased upon treatment with 
F1 in a dose-dependent manner (Figure 19). Several reports have indicated the 
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antiproliferative action of caffeic acid, chlorogenic acid and caffeoylquinic acid 
derivatives in different human cancer cells, evident at low concentrations, comparable 
with those found in biological fluids after ingestion of foods rich in phenolic acids.
54, 66, 80
 
Likewise, the presence of cyanidin 3-glucoside, even in small concentrations  may 
potentiate the anticarcinogenic effect exerted by chlorogenic acid in F1.
173, 174
 
 
 
 
Figure 19. F1 exerts a dose-dependent inhibition on cell viability. Representative 
evaluation of the concentration-dependent impact of F1 on the viability of human  
MDA-MB-435 breast cancer cells. MDA-MB-435 cells were incubated with various 
concentrations of extracts for 24 h and cell viability measured by MTT assay. 
Values are mean ± SD, n = 4. 
 
 
 
Molecular mechanisms behind the anticancer activity of F1 from peach BY00P6653  
F1 activates the mitogen-activated protein kinases (MAPKs) pathway  
We investigated the role of F1 on the activation of MAPK signaling pathway by 
western-blot analysis. Our results showed that F1 activated the extracellular signal-
regulated kinase (ERK1/2) in a time-dependent and dose-dependent manner (Figure 20). 
However, the other members of this family, the c–Jun NH2-terminal kinase (JNK), and 
the p38 MAPK were not activated. A late and weak activation of the transcription factor 
c-Jun was also observed. 
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The MAPK cell signaling pathway is frequently altered in a variety of human cancers; 
therefore modulation of these MAPK pathways by dietary compounds may provide novel 
strategies for the prevention and treatment of cancer.
143
 The ERK is generally activated in 
response to growth stimuli, whereas JNK and p38 are known to be simultaneously 
activated in response to a variety of cellular and environmental stresses that trigger 
apoptosis.
13
  
On the other hand, several reports have shown that activation of ERK1/2 promotes 
contrary cellular responses which may vary upon cellular context,
14, 15, 139
 and may 
commit the cell to apoptosis when it happens before the activation of p38 and JNK.
144
 
In addition, ERK1/2 activation can also contribute to cell death through the 
suppression of the antiapoptotic signaling molecule Akt.
175
 However, we did not find any 
effect of F1 treatment on the basal levels of either Akt nor Akt phosphorylation (data not 
shown).
175
 Key targets of MAPKs include several nuclear transcription factors, and c-Jun 
was found to be activated downstream of ERK1/2 phosphorylation.
176
 Even though 
previous studies in MDA-MB-435 cells supported the notion that c-Jun plays a critical 
role in apoptosiswhich implicates JNK activation in this process,
153
 we found that F1 
induced ERK1/2  prolonged activation and a delayed c-Jun phosphorylation 
independently of JNK and p38 activation. This was corroborated by blockage of ERK1/2 
phosphorylaton (Figure 20C). This finding is supported by a previous report indicating 
that c-Jun activity is enhanced by ERK phosphorylation, which may occur independently 
from the activation of JNKs.
177
 Additionally, ERK1/2 phosphorylation may trigger the 
activation of a large number of downstream molecules that may vary under different 
conditions, cell types and even cellular compartments.
176
  Among the downstream targets 
of ERK1/2 phosphorylation are the family of Bcl-2 proteins, which regulate apoptosis 
through the intrinsic mitochondrial apoptotic pathway.
120, 142
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Figure 20. Peach BY00P6653 phenolic acid fraction F1 activates MEK/ERK 
signaling pathway. (A) MDA-MB-435 cells were treated for 1, 6, 12, 24 and 36 h, 
with 150 mg chlorogenic acid equiv./L of F1. Control cells (c), cells were cultured 
with serum free medium for 36 h. Positive control (+c) cells received medium 
containing 10% FBS 6 h before harvesting. (B) MDA-MB-435 cells were treated 
with 25, 50, 100, 150 and 200 mg chlorogenic acid equiv./L of F1, control solvent (s) 
received same volume of vehicle (DMSO). (C) MEK1/2 inhibitor block FI-induced 
ERK activation and c-Jun activation. MDA-MB-435 cells treated with 150 mg 
chlorogenic acid equiv./L for 24 and 36h, 10 µM of U0126 was used for ERK1/2 
inhibition. Cell lysates were assesed by western blotting. Total β-actin was detected 
to show the same amount of protein load for all treatments. The data represent a 
typical experiment conducted three times with similar results. 
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F1 targets the mitochondrial apoptosis signaling pathway 
Several recent reviews have highlighted the role of natural compounds as novel anti-
cancer drugs that target mitochondria.
31, 178, 179
 We found that F1 activated the pro-
apoptotic Bax and Bak with no changes on levels of antiapoptotic Bcl-xL (Figure 21). 
The pro-apoptotic effects of Bax can be blocked by Bcl-xL, and the ratio of antiapoptotic 
Bcl-xL and pro-apoptotic Bax in the mitochondria determines survival or death following 
an apoptotic stimulus.
135
 The lower heterodimerization ratio of antiapoptotic Bcl-xL to 
proapoptotic Bax and Bak results in increase of mitochondrial membrane permeability 
due to Bax/Bak formation channels.
26, 180
 We also found that both cytochrome c release 
and Bax activation are downregulated by the inhibition of ERK1/2 phosphorylation 
(Figure 21B). Therefore, these findings suggest that F1 may have proapoptotic effects on 
MDA-MB-435 mediated by sustained activation of ERK1/2 which targets the 
mitochondrial apoptotic pathway. Similar effects on targeting the mitochondrial pathway 
have been reported for natural compounds that can selectively kill malignant cells at 
concentrations non-toxic to normal cells and tissues.
181
 Thus, the identification of novel 
compounds that may target the mitochondrial pathway may be considered in the 
development of anticancer drugs from natural compounds. 
In addition to the critical role that ERK1/2 may play in the mitochondrial apoptotic 
pathway, the ligand binding death receptor pathway (Fas ligand) may also indirectly 
trigger the activation of the mitochondrial pathway.
23, 26
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Figure 21. F1 activates the proapoptotic Bak  and Bax while the levels of 
antiapoptotic Bcl-xL remains constant. (A) MDA-MB-435 cells were treated with F1 
at doses: 0, 25, 50, 100, 150 and 200 mg chlorogenic acid equiv./L for 36 hours. (B) 
Cells treated with 20 mg/L of alfa-tocopheryl succinate (VES) for 24h were used as 
positive control for Bax activation and cytochrome c release, 10 µM of U0126 was 
used for MEK1/2 and the downstream ERK1/2 inhibition on F1 treated cells for 
24h. Cells were harvested and lysed for Western blot analysis. The data represent a 
typical experiment conducted three times with similar results. 
 
 
 
F1 activates the death receptor pathway   
We found that the treatment of MDA-MB-435 breast cancer cells with F1 induced a 
late activation of caspase-8 and the downstream executioner caspase-3 (Figure 22). This 
extrinsic pathway comprises a cross-talk with the intrinsic mitochondrial pathway. 
134, 167
 
Our results show that both the initiator caspase-8 and the executioner caspase-3 are 
activated at  ̴ 24h, whereas activation of caspase-9 is correlated with cytochrome c release 
and PARP (poly ADP-ribose) polymerase-1 cleavage, and occurs  ̴ 6 h after F1 treatment. 
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Indeed, the mitochondria pathway activation seems to be critical in F1-apoptosis 
induction. Along with cytochrome c release (which activates a caspase dependent cell 
death), mitochondrial membrane permeabilization also causes the release of pro-apoptotic 
factors such as apoptosis-inducing factor (AIF) and EndoG, which activate caspase-
independent cell death.  
 
 
 
 
Figure 22. F1 induces early caspase-9 activation and PARP cleavage in a time-
dependent manner and delayed  caspase-8 and caspase-3 cleavage. MDA-MB-435 
cells were treated with F1 (150 mg chlorogenic acid equiv./L) for the indicated 
times. Cleavage caspase 9, 3, 8 and PARP cleavage were assessed by Western blot 
analysis. Cells treated with 20 mg/L of α-tocopheryl succinate for 24h (VES) were 
used as positive control for cleavage caspase 9 and cytochrome c treated Jurkat cell 
extracts (cell signaling Technology, Beverly, MA ) was used as positive control for 
caspase 3 and 8 cleavage. Total β-actin was detected to show uniform protein load 
for all treatments. 
 
 
 
F1 induces apoptosis through a caspase-independent pathway  
So far, we have demonstrated that F1 targets the mitochondria apoptosis pathway 
through ERK1/2 activation. This is supported by our results showing how cytochrome c 
release to mitochondria decreases when the MEK1/2 inhibitor was used (Figure 23A), 
while to a lesser extent the cytochrome c release to the cytoplasma was found in the 
presence of either the pan-caspase inhibitor of JNK that could be upstream of c-Jun 
phosphorylation.
182
 Furthermore, we found that F1 induced Apoptosis-inducing factor 
C    1      6       12 24   36   +C Time (h)
Cleavage caspase 9
Cleavage caspase 3
Cleavage caspase 8
PARP cleavage
-β-Actin
69 
 
 
 
(AIF) and Endonuclease G (EndoG) translocation to the nucleus and this event seems to 
be downstream of ERK1/2 activation (Figure 23B). By inducing mitochondrial 
membrane permeabilization, several pro-apoptotic proteins such as cytochrome c, AIF, 
Smac/DIABLO, EndoG, and HtrA2/Omi can diffuse across the mitochondrial inner 
membrane to the cytosol.
183
 The nuclear translocation of AIF and EndoG has been 
reported to be responsible, at least in part, for DNA condensation and fragmentation, and 
subsequent cell death.
183
 This process may happen upon caspase activation
156
 and/or 
PARP cleavage
34, 183, 184
 or just as a result of mitochondrial dysfunction which triggers 
AIF translocation to the nucleus in a caspase independent pathway.
184
  
On the other hand, PARP is a nuclear protein implicated in DNA repair and one of the 
most utilized for the detection of apoptosis in many cell types.
131
 Once PARP is cleaved 
into its 24kDa and 89kDa fragments, it prevents DNA repair-induced survival.
130
 Even 
though caspase-3 may cleave PARP, the PARP cleavage time-response seems to be more 
directly influenced by the mitochondria pathway and associated to the release of the 
proapoptotic factor AIF.
34
 
The ERK1/2 sustained phosphorylation seems to play a key role in mitochondria 
permeabilization. Furthermore, our results showing the time-response for caspase-9 
activation, cytochrome c release, and PARP cleavage indicate that apoptosis induction by 
F1 on MDA-MB-435 is primarily mediated by a caspase independent pathway. Indeed, 
the contribution of caspases may reflect amplification but not an initiation of the 
apoptotic process (Figure 23A). Likewise, in Figure 23C we show how cell viability 
inhibition exerted by F1 was not reversed in the presence of the pan-caspase inhibitor 
(zVAD-fmk) as it was for the positive control VES (p < 0.05).  Caspase inhibitors have 
been reported to block VES-induced apoptosis of MDA-MB-435 breast cancer cells.
37
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Figure 23. Activation of ERK1/2 by F1 targets the mitochondrial pathway and 
induces cytochrome c release, AIF and EndoG nuclear translocation, reducing 
viability in a caspase independent manner. (A) MDA-MB-435 cells were treated 
with F1 (150 mg chlorogenic acid equiv./L) for 36 h. 10 µM of U0126 was used for 
MEK1/2 –ERK1/2 inhibition, 20µM of SP6000125 used for JNK-cJun inhibition, 
and 50 µM of zVAD-fmk  for caspase inhibition. The cytoplasm fraction was 
assessed for cytochrome c by western blotting. (B) Nuclear fractions of cells treated 
with F1 for 36 h were analyzed by western blots for AIF and EndoG. (C) MDA-MB-
435 cells were incubated with the vehicle (DMSO), 50µM  of zVAD-fmk for 1 h and 
then cultured in the absence or presence of F1 (150 mg chlorogenic acid equiv./L ) 
for 24h. Alfa-tocopheryl succinate (VES) was used as positive control for caspase-
dependent apoptosis. Values are mean ± SE, n=4. Different letters indicate 
significance at the p < 0.05 level. 
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In general, F1 appears to trigger apoptosis through the induction of mitochondrial 
changes as a primary intrinsic apoptotic pathway and late activation of caspase-8 as a 
secondary extrinsic apoptotic pathway. At this level there is a crosstalk between the death 
receptor pathway and the mitochondrial pathway 
23, 133
 (Figure 24). 
 
 
 
 
Figure 24. An overview of the pro-apoptotic mechanism exerted by peach 
BY00P6653 phenolic acid fraction F1 on MDA-MB-435 cells. Several factors may 
activate RAS, which then stimulates the Raf-MEK-MAPK pathway upstream of 
ERK1/2 phosphorylation. This event targets the mitocondrial pathway by Bax and 
Bak activation and cytochrome c release. The time response for caspase-9 activation 
and PARP cleavage correlates to ERK1/2 phosphorylation, whereas the delayed 
caspase-8 and caspase-3 activation suggest a secondary role of F1 induction of 
apoptosis. 
 
 
72 
 
 
 
Conclusion  
In conclusion, this study showed that phenolic compounds present in F1 of red flesh 
peach BY00P6653, exerts inhibition of cell viability and induces apoptosis on MDA-MB-
435 breast cancer cells by activation of the mitochondrial pathway mediated by sustained 
ERK1/2 phosphorylation, resulting in mitochondrial membrane permeabilization. The 
release of pro-apoptotic factors from mitochondria such as cytochrome c, EndoG and 
AIF, activated caspase-dependent and caspase-independent cell death. The potential 
applications of these compounds are as potentiators of therapeutic drugs that allow them 
to be effective at submaximal cytotoxic concentrations,
185, 186
 and/or for development of 
dietary supplements as strategy to inhibit or reverse the development of invasive breast 
cancer. The in vivo cancer suppression activity of these compounds deserves to be 
investigated. 
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CHAPTER V 
PEACH EXTRACTS SUPPRESS TUMOR GROWTH AND INVASION OF 
HUMAN MDA-MB-435 BREAST CANCER CELLS IN VIVO 
 
Synopsis 
Phenolic compounds extracted from a commercial variety of the yellow-fleshed peach 
Rich Lady (RL) were investigated for its tumor suppressive activity in vivo. The 
xenograft model allowed the assessment the dose-response of tumor growth rate and final 
weight of MDA-MB-435 transplanted tumors into athymic nude mice fed with RL 
phenolics. In addition, the anti-metastatic activity and modulation of tumor gene 
expression by RL phenolics was analyzed by RT-PCR.  The results showed that the 
mixture of phenolics on RL extract when administered to mice at the highest doses (0.8 
and 1.6 mg/day) effectively suppressed the palpable tumor-growth rate. Even though, 
doses lower than 0.8 mg/day appeared not to be effective in delaying the palpable tumor 
growth, a dose-dependent decrease trend in final tumor weight was found, and most 
importantly, RL phenolics induced a dramatic decrease in lung metastasis at all doses 
used. Downregulation of metalloproteinase-2 (MMP-2), metalloproteinase-13 and 
metalloproteinase-3 gene expression may be some of the molecular targets for anti-
metastatic activity of RL phenolics.  However the involvement of other members of the 
metalloprotease family as well as pro-angiogenic and cell motility factors, which may be 
differentially regulated in situ by RL phenolics deserves further investigation.  
  
Introduction 
Breast cancer is the most common malignant disease in Western women. Death, and 
most of the complications associated with breast cancer are due to metastasis. The 
American Cancer Society has estimated that there will be 182,460 new cases of invasive 
breast cancer among women in the US during 2008.
1
  
Recently, the rates of metastasis and mortality in breast cancer patients have decreased 
as a result of early diagnosis by mammographic screening and the implementation of 
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adjuvant therapy. The adjuvant therapy can help to eradicate breast tumor cells that might 
have already spread to distant sites by the time of diagnosis. However, chemotherapy has 
a wide range of acute and long-term side effects that substantially affect the patient‟s 
quality of life. Nowadays more than 80% of the patients diagnosed with primary breast 
cancer receive adjuvant chemotherapy, although only about 40% of the women really 
need it. Therefore, women who would be cured by local treatment alone, which includes 
surgery and radiotherapy, are being „over-treated‟ and suffer the toxic side effects of 
chemotherapy unnecessarily.
2
 
Mouse models have made an important contribution to the understanding of breast 
cancer progression and metastasis. The xenograft model is commonly used to investigate 
the growth of breast cancer cell lines in an in vivo environment, which resembles the 
complex interactions that are involved in breast tumor formation and progression.
81
 The 
xenograft models are often used in metastasis research because they offer excellent 
insights into invasion properties and progression studies,
81
 and constitute an important 
tool to test and validate novel treatment strategies. 
A tumor is defined as a local uncontrolled growth of abnormal tissue consisting of 
transformed cells, as well as other cell types including fibroblasts, macrophages, 
endothelial cells and connective tissue components known as the stroma.
187
 Tumor 
metastasis is a multistep process involving the invasion of primary tumor cells into the 
surrounding tissue and their propagation at distal sites. Tumor cells influence and 
manipulate the stroma in such a way that the latter produces a permissive and supportive 
environment, which helps facilitate the growth of the carcinoma. To establish a 
metastasis, tumor cells have to invade their surrounding host tissue, enter the circulatory 
blood stream, arrest in capillary beds of distant organs, invade the host tissue and 
proliferate.
2, 188
 Primary breast cancer cells metastasize through the blood vessels to 
various distant organs, preferentially, to the lung, liver and bones.
2
 Tumors as small or 
less than 2 mm in diameter already receive a vascular blood supply,
189
 therefore, it is 
likely that cancer cells have spread throughout the body years before they are first 
detected.
189
 
Some of the biomolecules playing a key role in development of breast cancer 
metastasis are the matrix metalloproteases (MMP), vascular endothelial growth factor 
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(VEGF) and the transmembrane protein E-cadherin (E-cad). The MMP family of 
proteolytic enzymes, degrade constituents of the extracellular matrix surrounding 
invasive breast carcinomas.
190
 The expression of vascular endothelial growth factor 
(VEGF) has been identified as a key component for tumor growth, metastasis and 
angiogenesis.
191, 192
 Angiogenesis is characterized by migration and proliferation of 
endothelial cells and the maturation of new blood vessels that would supply oxygen and 
nutrients to tumor cells in response to local pro-angiogenic factors and activation of 
matrix metalloproteases.
193
 E-cad is the main component of the adherent cell–cell 
junction of epithelial cells. Inactivating E-cad in vivo results in the disruption of luminal 
epithelium with the release of individualized cells in the lumen.
194
 Equally, maintenance 
of E-cad in invasive tumors can block tumor progression in the mouse model.
195
 
Repression of the E-cad gene in breast carcinomas has been inversely correlated to 
expression of Snail or Slug transcription factors that act as transcriptional repressors.
196
 
In this context, the specific phenolic compounds identified in peaches and plums
51
 
have shown to inhibit tumor growth and metastasis through xenograft models. For 
example, cyanidin 3-glucoside, as a component of an anthocyanin rich extract, was 
reported to inhibit tumor growth in vivo,
96, 97
 and invasion via repression of 
metalloproteases;
97
 the wine anthocyanins delphinidin and cyanidin inhibited VEGF 
expression through the p38 MAPK pathway,
197
 proanthocyanidins suppressed the tumor 
growth and increased the anti-tumor activity of the chemotherapeutic doxorubicin;
98, 99
 
quercetin inhibited the growth and exhibited pro-apoptotic activities in xenografted 
MDA-MB 435 cells into nude mice;
52
 treatment with caffeic acid derivatives induced a 
significant dose dependent decrease in tumor growth and reduced the number of mitotic 
cells.
95
 Therefore, the potential of peach phenolics as tumor-suppressive and anti-
metastatic agents deserves to be investigated. The results from this study could lead to 
translational research toward a rational application of natural chemopreventive 
compounds as adjuvant therapy to potentiate the inhibitory effects of non-toxic doses of 
commonly used chemotherapeutics. 
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Materials and Methods 
Preparation of peach extracts 
The commercial variety of yellow-fleshed peach „Rich Lady‟ (RL) grown in 
California, were collected at a mature firm stage and stored at 2-4 °C until use (less than 
5 days). Upon arrival at Texas A&M University, the fruits after removing the stones were 
frozen and kept at -20 °C until use. 100 g of frozen fruit (flesh plus skin) was blended 
with 300 mL of methanol and left at 4 °C overnight. The methanolic extracts were 
filtered through whatman #1 filter paper and the methanol evaporated at 45 °C using a 
rotavapor (Büchi, Switzerland). Aqueous extracts were frozen at -80 ºC and freeze-dried 
(FTS® Systems, Inc., Stone Ridge, NY) at -50 ˚C and at 200 mmHg of pressure. Dry 
extracts were re-dissolved in sterile water and sterile filtered before use. Doses were 
calculated based on the content of total phenolics.
103
  
Cell culture 
The MDA-MB-453estrogen receptor-negative human breast cancer cells were obtained 
from the American Type Culture Collection (ATCC, Manassas, VA). Cells were cultured 
using Dulbecco‟s modified Eagle‟s medium (DMEM) with L-glutamine, 4.5 g/L glucose, 
without sodium pyruvate, and supplemented with 10% (v/v) (FBS) and 1% streptomycin-
penicillin antibiotic mix. The culture medium was supplied by Invitrogen (Grand Island, 
NY). Cells were maintained at 37 ºC with a humidified 5% CO2 atmosphere. 
Animals 
Female athymic nude mice (homocygous Nu-/-), aged 3 to 4 weeks, were purchased 
from Harlan Laboratories (Houston, TX) and maintained in a ventilated rack system. 
Irradiated food and autoclaved water were provided ad libitum. Experiments were 
approved by the Institutional Animal Care and Use Committee at Texas A&M University 
(College Station, TX). The mice were allowed to adjust to their environment for 4 days 
before initiation of the experiments. 
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Antitumor efficacy study 
This study was performed in two phases. The first phase allowed us to find out the 
range of acive concentrations of peach RL extract and the second phase we tested the 
most active concentration and went beyond that concentration to find out the threshold of 
active concentrations. MDA-MB-435 cells (5 x 10
5
) suspended in 100µl of DME-50% 
Matrigel (BD Bioscience, San Jose, CA) were injected subcutaneously into each flank of 
the nude mice. Injections were carried out 5 days before treatment with peach extracts 
(day 0). On day 0, mice used in the first phase of the study were randomly divided into 
four groups (n = 3 for each group) to be fed by oral gavage with sterile water (control) 
and peach extracts (0.2, 0.4, and 0.8 mg phenolics/day). For the second phase of the 
study, three groups of xenografted mice (n = 5 for each group) were fed with sterile water 
(control) and peach extracts (0.8, and 1.6 mg phenolics/day). In addition two groups in 
which no tumor cells were injected were used as a negative control to evaluate possible 
toxicity of the highest doses (0.8 and 1.6 mg/L). Tumor volume was measured with 
calipers every three days. The estimated tumor volume was calculated by the formula: a
2 
x b/2, where “a” and “b” are the short and the long axis of the tumor, respectively. All 
procedures were conducted under aseptic conditions in a laminar flow hood. At the end 
of the study, (day 24), mice were sacrificed following institutional regulations, tumors 
and lungs were removed, weighed, and frozen for subsequent RNA analysis. 
RNA isolation 
Tumor and lung samples were mechanically pulverized in liquid nitrogen. RNA was 
extracted using Trizol (Invitrogen) according to the manufacturer‟s protocol. Purification 
was carried out using the RNeasy mini columns (Qiagen, Clifton Hill, Australia). 
Quantification of RNA was established based on A260nm and A280nm using an ND-
1000 spectrophotometer (Nanodrop Technologies, Rockland, DE).  
cDNA synthesis and quantitative PCR 
 cDNA was reverse transcribed using 270 ng or 1890 ng of total RNA extracted from 
tumors or lungs respectively using oligo (dT) and Superscript II Reverse Transcriptase 
(Invitrogen), following the manufacturer instructions. Real-time, quantitative PCR was 
done on a 7500 Fast Real-Time PCR System. Briefly, PCR was done using the SYBR 
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Green PCR Master Mix kit (Applied Biosystems, Foster City, CA), cDNA templates and 
primers. The reaction volume was 25 µL and all primers were used at a final 
concentration of 100nmol/L. Thermocycling was initiated with a 10-minute, 95ᵒC 
enzyme activation step followed by 40 cycles of 95ᵒC for 15 seconds, and 60ᵒC for 1 
minute. Human TBP and mouse β-actin were used as normalizing genes for lungs and 
tumors respectively. Real-time PCR data was analyzed by the ∆∆CT method.198  
Primers 
Primers encoding human VEGF, SLUG, MMP-2, MMP-1, MMP-3, MMP-9, MMP-
13, hβ2G, and hTBP and mouse mβ-actin genes were purchased from Integrated DNA 
Technologies, Inc. (San Diego, CA). Primer sequences, listed in Table 5 were designed 
using Primer Express® software v2.0 from Applied Biosystems (Foster City, Ca). 
Product specificity was examined by dissociation curve analysis.  
 
 
     Table 5. Primer sequences.  
Gene  Primer Sequence 
hß2G-RTF1 CGC TCC GTG GCC TTA GC 
hß2G-RTR1 AAT CTT TGG AGT ACG CTG GAT AGC 
hTBP-RTF1 TGC ACA GGA GCC AAG AGT GAA 
hTBP-RTR1 CAC ATC ACA GCT CCC CAC CA 
mß-actin-RTF1 GCA ACG AGC GGT TCC G 
mß-actin-RTR1 CCC AAG AAG GAA GGC TGG A 
hVEGF-RTF1 TAC CTC CAC CAT GCC AAG TG 
hVEGF-RTR1 GAT GAT TCT GCC CTC CTC CTT 
hMMP-2-RTF1 CTG ATG GCA CCC ATT TAC ACC TA 
hMMP-2-RTF1 GAG CTC CTG AAT GCC CTT GA 
hMMP-9-RTF2 TGG GCA AGG GCG TCG TGG TTC 
hMMP-9-RTR2 TGG TGC AGG CGG AGT AGG ATT 
hMMP-3-RTF1 TTC CTG ATG TTG GTC ACT TCA GA 
hMMP-3-RTR1 TCC TGT ATG TAA GGT GGG TTT TCC 
hSLUG-RTF1 GGC TGG CCA AAC ATA AGC A 
hSLUG-RTR1 CCT TGT CAC AGT ATT TAC AGC TGA AA 
MMP-13-RTF1 ATT AAG GAG GAT GGG GAC 
MMP-13-RTR1 CCC AGG AGG AAA AGC ATG AG 
MMP-1-RTF1 TTT GAT GGA CCT GGA GGA AAT C 
MMP-1-RTR1 TGA GCA TCC CCT CCA ATACC 
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Statistical analysis 
Quantitative data represent mean values with the respective standard deviation (SD) or 
standard error of the mean (SE) corresponding to 3 or more replicates. Data were 
analyzed by one-way analysis of variance (ANOVA) using SPSS version 15.0 (SPSS 
Inc., Chicago, IL). Post-hoc Tukey pairwise comparisons were used (p<0.05). 
 
Results and Discussion 
Effect of RL extracts on body weight 
The final body weight and weight gain did not differ significantly among the 
experimental groups over study (Figure 25). Likewise, the appearance of major organs 
including kidney and liver were not visibly affected. This suggests no toxicity or potential 
adverse effect on the major organs due to peach phenolics feeding. 
  
 
 
 
Figure 25. The effect of peach extract treatments on weight gain of athymic nude 
mice. The (-) 0.8 and (-) 1.6 mg/day were the no xenografted mice used as negative 
controls.Values are average of three or more replicates ± SE of the mean. 
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Effect of RL extracts on the palpable tumor growth and final tumor weight  
The palpable tumor volume (cm
3
) during the study was visibly lower in the 
experimental groups fed with 0.8 and 1.6 mg total phenolics/day compared to the other 
treatments or the control (Figure 26). The weights of tumors at the end showed a dose 
dependent decrease effect (Figure 26-B). Treatments by oral gavage with RL phenolics at 
0.2, 0.4, 0.8 and 1.6 mg/day , decreased the final tumor weight by 9.5, 13 and 23.3 and 
23.1% respectively. 
 
 
 
 
Figure 26. Phenolic compounds from Rich Lady (RL) decrease the palpable tumor 
growth-rate (A),  and tumor weight (B). Untreated mouse showing tumor with 
visible signals of angiogenesis (C). Tumor in mouse treated with 0.8 mg of RL 
phenolics/day (D). Values represented the mean ± SE (* p< 0.05, n = 5). 
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Studies have reported the in vivo growth inhibitory activity of most of the phenolic 
compounds present in RL peach extracts.
52, 93, 96, 98
 However, some of these studies used a 
subcutaneous (s.c.) injection to deliver the bioactive compounds.
52
 Our results are 
relevant, because the intragastrointestinal delivery resembles the intake of phenolics 
through a diet rich in fruits and vegetables, or dietary supplements made from plant 
extracts, especially those plant foods that may contain a phenolic profile similar of to 
stone fruits.
51
  Indeed, the bioactive compounds can pass through the intestinal barrier 
and effectively reach the tumors, thus the in vitro tumor growth inhibitory activity of RL 
extracts can be translated to in vivo efficacy. 
Effect of RL phenolic extract on the invasive potential of MDA-MB-435 
The anti-metastatic activity of RL extracts in vivo was assessed by analyzing gene 
expression in the lungs of the sacrificed mice. The mRNA levels of the hβ2G (human β-2 
globulin) were normalized to the mβ-actin (mouse β-actin) gene expression in lung 
tissues and analyzed by RT-PCR (Figure 27). 
 
 
 
Figure 27. Dose dependent effect of RL phenolics on the human β-2 globulin (hβ2G) 
gene expression on mouse lungs. Dose dependent hβ2G gene expression (A), values 
are averages ± SE (n ≥ 2). The results from the second phase of the study show the 
basal level of hβ2G gene expression in negative controls (no xenografted mice) (B), 
values are averages ± SE (n ≥ 3). Different letters indicate significance at P < 0.05. 
 
 
Doses (mg/day)
0 0.8 1.6 (-) 0.8 (-)  1.6
R
e
la
ti
v
e
 m
R
N
A
  
 l
e
v
e
ls
0
20
40
60
80
100
120
140
160
(A)
(B)
(a)
(a,b)
(b)
(c)
Doses (mg/day)
0 0.2 0.4 0.8
R
e
la
ti
v
e
 m
R
N
A
  
le
v
e
ls
0
20
40
60
80
100
120
140
160
(c)
(a)
(b)
(b)
(b)
82 
 
 
 
Treatment with RL extracts significantly decreased the human β-2 globulin (hβ-2G) 
gene expression on mouse lungs, this suggests that RL phenolics have potential in 
preventing progression and metastasis in distant organs. Even the lower doses (0.2 and 
0.4 mg/day), that appeared not to be effective on tumor growth-rate suppression, showed 
a significant anti-metastatic activity. This is consistent with previous studies showing the 
anti-metastatic potential compounds present in peach extracts. Quercetin, was found to 
potentiate the inhibitory effect of a non-toxic dose of the chemotherapeutic cisplatin and 
inhibited more effectively then tamoxifen the colonization of the murine melanoma B16-
BL6 in the lungs in a dose-dependent manner..
199
 Chlorogenic acid was found to be a 
strong matrix metalloprotease-9 inhibitor,
200
 apple polyphenols also containing 
chlorogenic acid, epicatechin and procyandins inhibited the growth and the metastasis of 
AH109A hepatomas in vivo.
94
 In general, several reports are currently identifying plant 
polyphenolics as anti-invasive cancer agents.
201-203
  
This is relevant, because approximately 10-15% of patients with breast cancer develop 
distant metastasis,
2
 due to the inherent metastatic capacity of breast tumors. To reduce the 
risk of metastasis, patients with primary tumors are sometimes over-treated with adjuvant 
chemotherapy and suffer the toxic side effects that reduce their quality of life 
unnecessarily.
2
 Therefore, the mixture of phenolics present in RL extracts may constitute 
a novel chemopreventive tool in the combination therapy when primary cancer is 
diagnosed.
2
  
The effect of RL phenolic extract on the tumor gene expression  
There are several proteins associated with invasion and metastasis that can be 
regulated at the level of gene expression. Among these proteins are the matrix 
metalloproteinases (MMPs), which are important targets in breast cancer progression due 
to their role in facilitating tumor invasion and metastasis. Our results showed a dose-
dependent decrease on MMP-2 gene expression on tumors of mice treated with RL 
extracts (Figure 28). The production of MMPs allows for the degradation of surrounding 
extracellular matrix and eventual development of new blood vessels.
190
 Specifically 
MMP-2 expression, has been reported to be dysregulated in breast cancer invasion and 
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metastasis.
204
 Therefore, RL phenolics may be promising therapeutic agents that block 
tumor progression by targeting MMP-2.  
 
 
 
Figure 28. Dose dependent effect of RL phenolics on the human MMP-2 gene 
expression on xenografted tumors. In (A) values are averages ± SE (n ≥ 2). The 
results from the second phase of the study (B) show significance at P < 0.05, values 
are averages ± SE (n ≥ 5). 
 
 
 
Similar results were found in the second phase of the study for MMP-1, MMP-13 and 
MMP-3 (Figure 29).  However, RL treatments apparently did not modulate the gene 
expression of MMP-9, VEGF and SLUG on xenografted tumors. 
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Figure 29. Gene expression on xenografted MDA- MB-435 tumors. Phase I of the study (n = 3) (A). Phase II of the study (n=5) 
(B). Values are means ± SE. Different letters indicates significance at P < 0.05.  
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However, these biomolecules directly related to tumor growth, degradation of 
extracellular matrix, generation of new blood vessels and cell motility to sustain survival, 
proliferation and invasion to distant organs could be localized on the invasive fronts. In 
addition, MMP activity can be regulated at least at three levels: transcription/translation, 
proteolytic activation of the zymogen, and inhibition of the active enzyme.
190
 Likewise, 
the tumor-associated stroma has shown to be an important site of VEGF production that 
is required for growth of new blood vessels and tumor nutrient and oxygen supply.
205
 
Similar location is expected for the expression of MMP and SLUG as well.
196, 205
 These 
areas could represent invasive fronts linked to local progression in connection with 
increased invasiveness. The use of techniques such an in situ hybridization or 
immunohistochemistry may allow the detection of differences on localized gene 
expression. 
 
Conclusion  
The in vitro antitumor activity of phenolic compounds extracted from the yellow-
fleshed peach Rich Lady (RL) variety on MDA-MB-435 estrogen receptor negative 
breast cancer cells has been confirmed in vivo. The xenografted tumors of the highly 
metastatic MDA-MB-435 cells were effectively decreased in weight and volume when 
mice were fed with RL extracts without weight loss or toxicity to the main organs. The 
mixture of phenolics extracted from RL decreased the tumor growth rate at only the 
highest dose (0.8mg/day). At the end of the study, a RL phenolics dose-dependent 
response was found for tumor weight. Most importantly, the metastasis on lungs was 
dramatically decreased even by the lowest dose of RL phenolics that appeared not to be 
effective against tumor growth-rate. The potential targets of RL phenolics for anti- 
metastatic activity are the metalloproteases (MMPs), specifically MMP-2 was found to be 
downregulated at the gene expression level on tumors. While the other MMPs analyzed, 
the VEGF and SLUG were not found to be transcriptional regulated in the homogenized 
tumor tissue, the post transcription regulation of MMPs as well as the localized gene 
expression of VEGF, SLUG and MMPs in the tumor-stroma boundaries warrants further 
investigation. This is the first study to disclose the anticancer activity and potential anti-
metastatic application of RL phenolics in vivo. These findings support the potential use of 
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RL phenolics as chemopreventive and therapeutic novel compounds for metastasis. 
Careful elucidation of the molecular mechanisms underlying the antimetastatic action of 
RL phenolics may amplify its clinical applications. 
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CHAPTER VI 
GENERAL CONCLUSIONS AND RECOMMENDATIONS 
 
Peaches and plums contain a mixture of phenolic compounds that preferentially inhibit 
the growth of the estrogen independent MDA-MB-435 breast cancer cells over either the 
estrogen dependent MCF-7 breast cancer cells or the breast epithelial MCF-10A cells. 
When polyphenols were fractionated into different groups, the phenolic acids fraction F1 
from the rich Rich Lady (RL) peach and its major components chlorogenic and neo-
chlorogenic were found to suppress the growth of MDA-MB-435 cells with no or low 
toxicity on the non-cancerous MCF-10A cells.  
Our study on molecular mechanisms targeted by the RL phenolic acids fraction F1, 
chlorogenic acid and neo-chlorogenic acid showed that the relatively higher growth-
inhibition activity exerted by neo-chlorogenic acid may be related to its unique ability to 
downregulate the Akt cell survival pathway.  
Induction of apoptosis exerted by the tested compounds involved activation of 
extrinsic and intrinsic pro-apoptotic pathways. The extrinsic pathway was activated by 
targeting the death receptor pathway, which activates the initiator caspase-8 and the 
downstream effectors caspase-6 and -7. The intrinsic mitochondrial apoptotic pathway 
was triggered by the activation of the pro-apoptotic Bax, and increasing the ratio 
Bax/Bcl-2 in favor of outer mitochondria membrane permeabilization. Both the extrinsic 
death receptor pathway and MAPK activation mediated by ERK1/2 and p38 
phosphorylation, were shown to play important roles on the activation of pro-apoptotic 
Bax, mitochondria permeabilization and subsequent release of the pro-apoptotic proteins 
AIF, EndoG and cytochrome c.  
In contrast, the fraction F1 extracted from the red flesh peach BY00P6653 genotype, in 
which chlorogenic acid and cyanidin 3 β-glucoside were identified, induced apoptosis on 
MDA-MB-435 breast cancer cells through the intrinsic mitochondrial pathway mediated 
by sustained ERK1/2 phosphorylation as a primary pro-apoptotic mechanism. The late 
caspase activation indicated that the extrinsic apoptotic pathway plays a secondary role 
on the F1-induction of apoptosis. 
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The in vitro antitumor activity of RL phenolics were further confirmed in vivo by using 
a xenograft model. The growth of tumors of MDA-MB-435 cells was decreased in weight 
and volume when nude mice were fed with RL extracts without signals of weight loss or 
toxicity on main organs. Most importantly, the metastasis on lungs was significantly 
lower even by the doses of RL phenolics that appeared not to be effective against tumor 
growth-rate. The RL phenolics may exert their anti- metastatic activity by targeting the 
metalloproteinases (MMPs), specifically the gene expression of MMP-2 in tumors was 
found to be downregulated in a dose-dependent manner. We suggest further analysis on 
the localized gene expression of other MMPs family members as well as the 
proangiogenic VEGF and the transcriptional cell migration repressor SLUG. These 
results have important clinical implications because the active compounds in RL extracts, 
chlorogenic acid and neo-chlorogenic acid are widespread among food plants and 
constitute an integral part of the human diet. Careful elucidation of the molecular 
mechanisms underlying the antimetastatic action of RL phenolics may amplify its clinical 
applications. 
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